Scar ablation combined with LP/OEC transplantation	1
Scar ablation	1
LP/OEC transplantation	29
anatomical recovery and P0-positive myelination in chronically contused spinal cord of rats Shu-xin	61
anatomical recovery and P0-positive myelination	61
chronically contused spinal cord of rats Shu-xin	112
chronically contused spinal cord	112
rats Shu-xin	148
Zhanga , , Fengfa Huanga , Mary Gatesa , Eric G. Holmberga , b We have successfully removed an existing glial scar in chronically contused rat spinal cord using a rose Bengal-based phototoxic method	162
Zhanga , , Fengfa Huanga , Mary Gatesa , Eric G. Holmberga , b We have successfully removed an existing glial scar in chronically contused rat spinal cord using a rose	162
Zhanga	162
Fengfa Huanga , Mary Gatesa , Eric G. Holmberga	172
Fengfa Huanga	172
Mary Gatesa	187
Eric G. Holmberga	200
b We have successfully removed an existing glial scar in chronically contused rat spinal cord using a rose	219
b	219
We	222
an existing glial scar in chronically contused rat spinal cord using a rose	251
an existing glial scar	251
chronically contused rat spinal cord	277
a rose	320
Bengal-based phototoxic method	327
The purpose of this study	359
The purpose	359
this study	374
scar ablation benefits	402
the anatomical recovery by cell/tissue transplantation	425
the anatomical recovery	425
cell/tissue transplantation	452
a more permissive physical and biochemical environment for axonal growth , which may lead to functional recovery	499
a more permissive physical and biochemical environment	499
axonal growth , which may lead to functional recovery	558
axonal growth	558
functional recovery	591
scar ablation	630
we	645
lamina propria -LRB- LP -RRB- of the olfactory mucosa alone or in combination	661
lamina propria -LRB- LP -RRB-	661
lamina propria	661
LP	677
the olfactory mucosa alone or in combination	684
the olfactory mucosa	684
combination	717
olfactory ensheathing cells -LRB- OEC -RRB-	743
olfactory ensheathing cells	743
OEC	772
the lesion cavity	782
6 weeks	800
contusion injury	814
NYU impactor device , 25 mm height setting	832
NYU impactor device	832
25 mm height setting	853
spinal cord segment T10 of adult female Long -- Evans rats	878
spinal cord segment T10	878
adult female Long -- Evans rats	905
Long	918
Evans rats	923
Evans	923
rats	929
Sixteen weeks	935
scar ablation and transplantation	955
we	990
the initial repaired tissue	1004
remarkable reduction or disappearance of the lesion cavity and integration of repaired tissue with the spared tissue	1069
remarkable reduction or disappearance	1069
the lesion cavity and integration of repaired tissue with the spared tissue	1110
the lesion cavity and integration	1110
repaired tissue with the spared tissue	1147
repaired tissue	1147
the spared tissue	1168
histological repair of damaged cord tissue at the injury epicenter	1205
histological repair	1205
damaged cord tissue at the injury epicenter	1228
damaged cord tissue	1228
the injury epicenter	1251
Glial scar reformation	1273
ablation due to the tissue repair	1328
ablation	1328
the tissue repair	1344
addition	1366
the injury epicenter P0 -LRB- myelin glycoprotein P-zero -RRB- - positive myelination formed by Schwann cells , which are known to myelinate regenerating and demyelinated axons	1379
the injury epicenter P0	1379
myelin glycoprotein P-zero	1404
positive myelination formed by Schwann cells	1432
positive myelination	1432
Schwann cells	1463
myelinate regenerating	1497
axons	1537
number	1576
the control animals	1597
BBB open-field scale	1647
a significant improvement of locomotor function	1668
a significant improvement	1668
locomotor function	1697
this study	1736
the possible reasons	1748
Introduction	1789
many treatment approaches including cell transplantation	1808
many treatment approaches	1808
cell transplantation	1844
functional recovery in acute spinal cord injury -LRB- SCI -RRB- models	1895
recovery in acute spinal cord	1906
recovery	1906
acute spinal cord	1918
SCI	1944
the same or similar treatments	1957
chronic spinal cord injury models -LRB- Azanchi et al. , 2004 ; Houle and Tessler , 2003 ; Tetzlaff et al. , 2010 -RRB-	2021
chronic spinal cord injury models	2021
Azanchi et al. , 2004 ; Houle and Tessler , 2003 ; Tetzlaff et al. , 2010	2056
Azanchi	2056
et al. , 2004 ; Houle and Tessler , 2003 ; Tetzlaff et al. , 2010	2064
et al. , 2004	2064
et al.	2064
2004	2072
Houle and Tessler , 2003	2078
Houle and Tessler	2078
2003	2097
Tetzlaff et al. , 2010	2103
Tetzlaff	2103
et al. , 2010	2112
et al.	2112
2010	2120
studies	2136
neurons with axonotmesis in the chronically injured spinal cord	2155
neurons	2155
axonotmesis in the chronically injured spinal cord	2168
axonotmesis	2168
the chronically injured spinal cord	2183
the ability	2234
the glial scar	2261
the elongation of regenerating axons -LRB- Bareyre , 2008 ; Houle , 1991 ; Kobayashi et al. , 1997 ; Siebert et al. , 2010 ; Silver and Miller , 2004 ; Steeves and Zwimpfer , 1997 -RRB-	2295
the elongation	2295
regenerating axons -LRB- Bareyre , 2008 ; Houle , 1991 ; Kobayashi et al. , 1997 ; Siebert et al. , 2010 ; Silver and Miller , 2004 ; Steeves and Zwimpfer , 1997 -RRB-	2313
regenerating axons	2313
Bareyre , 2008 ; Houle , 1991 ; Kobayashi et al. , 1997 ; Siebert et al. , 2010 ; Silver and Miller , 2004 ; Steeves and Zwimpfer , 1997	2333
Bareyre , 2008 ; Houle , 1991 ; Kobayashi et al. , 1997 ; Siebert et al. , 2010 ; Silver and Miller	2333
Bareyre , 2008	2333
Bareyre	2333
2008	2342
Houle , 1991	2348
Houle	2348
1991	2355
Kobayashi et al. , 1997	2361
Kobayashi	2361
et al. , 1997	2371
et al.	2371
1997	2379
Siebert et al. , 2010	2385
Siebert	2385
et al. , 2010	2393
et al.	2393
2010	2401
Silver and Miller	2407
Silver	2407
Miller	2418
2004 ; Steeves	2426
2004	2426
Steeves	2432
Zwimpfer , 1997	2444
Zwimpfer	2444
1997	2454
The cessation of axonal elongation via glial inhibition	2461
The cessation	2461
axonal elongation via glial inhibition	2478
axonal elongation	2478
glial inhibition	2500
the failure of functional recovery	2551
the failure	2551
functional recovery	2566
a chronically injured spinal cord -LRB- Bradbury and Carter , 2011 ; Davies et al. , 1997 ; Houle and Reier , 1988 ; McKerracher , 2001 ; Silver and Miller , 2004 -RRB-	2589
a chronically injured spinal cord	2589
Bradbury and Carter , 2011 ; Davies et al. , 1997 ; Houle and Reier , 1988 ; McKerracher , 2001 ; Silver and Miller , 2004	2624
Bradbury and Carter	2624
2011 ; Davies et al. , 1997 ; Houle and Reier , 1988 ; McKerracher , 2001 ; Silver and Miller	2645
2011	2645
Davies et al. , 1997 ; Houle and Reier , 1988 ; McKerracher , 2001 ; Silver and Miller	2651
Davies	2651
et al. , 1997 ; Houle and Reier , 1988 ; McKerracher , 2001 ; Silver and Miller	2658
et al. , 1997	2658
et al.	2658
1997	2666
Houle and Reier , 1988	2672
Houle and Reier	2672
1988	2689
McKerracher , 2001	2695
McKerracher	2695
2001	2708
Silver and Miller	2714
Silver	2714
Miller	2725
2004	2733
Several studies	2740
significant axonal growth into the graft	2776
significant axonal growth	2776
the graft	2807
the removal of inhibitory chondroitin sulfate proteoglycans -LRB- CSPG -RRB- and astrocytic scar tissue from the lesion site prior to transplantation -LRB- Bradbury et al. , 2002 ; Carter et al. , 2011 ; Garcia-Alias et al. , 2009 ; Houle and Tessler , 2003 ; Hulsebosch , 2002 ; Tom et al. , 2009 -RRB-	2826
the removal of inhibitory chondroitin sulfate proteoglycans -LRB- CSPG -RRB-	2826
the removal	2826
inhibitory chondroitin sulfate proteoglycans -LRB- CSPG -RRB-	2841
inhibitory chondroitin sulfate proteoglycans	2841
CSPG	2887
astrocytic scar tissue from the lesion site prior to transplantation -LRB- Bradbury et al. , 2002 ; Carter et al. , 2011 ; Garcia-Alias et al. , 2009 ; Houle and Tessler , 2003 ; Hulsebosch , 2002 ; Tom et al. , 2009 -RRB-	2897
astrocytic scar tissue	2897
the lesion site prior to transplantation -LRB- Bradbury et al. , 2002 ; Carter et al. , 2011 ; Garcia-Alias et al. , 2009 ; Houle and Tessler , 2003 ; Hulsebosch , 2002 ; Tom et al. , 2009 -RRB-	2925
the lesion site prior to transplantation	2925
the lesion site	2925
transplantation	2950
Bradbury et al. , 2002 ; Carter et al. , 2011 ; Garcia-Alias et al. , 2009 ; Houle and Tessler , 2003 ; Hulsebosch , 2002 ; Tom et al. , 2009	2967
Bradbury	2967
et al. , 2002 ; Carter et al. , 2011 ; Garcia-Alias et al. , 2009 ; Houle and Tessler , 2003 ; Hulsebosch , 2002 ; Tom et al. , 2009	2976
et al. , 2002	2976
et al.	2976
2002	2984
Carter et al. , 2011	2990
Carter	2990
et al. , 2011	2997
et al.	2997
2011	3005
Garcia-Alias et al. , 2009	3011
Garcia-Alias	3011
et al. , 2009	3024
et al.	3024
2009	3032
Houle and Tessler , 2003	3038
Houle and Tessler	3038
2003	3057
Hulsebosch , 2002	3063
Hulsebosch	3063
2002	3075
Tom et al. , 2009	3081
Tom	3081
et al. , 2009	3085
et al.	3085
2009	3093
These results	3100
both scar ablation and cell transplantation	3127
scar ablation	3132
cell transplantation	3150
one necessary component for successful treatment of a chronic spinal cord injury	3180
one necessary component	3180
successful treatment of a chronic spinal cord injury	3208
successful treatment	3208
a chronic spinal cord injury	3232
The glial scar	3262
an important target	3293
regeneration research in spinal cord injury	3317
regeneration research	3317
spinal cord injury	3342
few studies	3371
successful removal of an existing glial scar -LRB- Fawcett and Asher , 1999 ; Gimenez y Ribotta et al. , 2002 ; Hu et al. , 2010 ; Kwon and Tetzlaff , 2001 ; Schwab and Bartholdi , 1996 -RRB-	3414
successful removal	3414
an existing glial scar -LRB- Fawcett and Asher , 1999 ; Gimenez y Ribotta et al. , 2002 ; Hu et al. , 2010 ; Kwon and Tetzlaff , 2001 ; Schwab and Bartholdi , 1996 -RRB-	3436
an existing glial scar	3436
Fawcett and Asher , 1999 ; Gimenez y Ribotta et al. , 2002 ; Hu et al. , 2010 ; Kwon and Tetzlaff , 2001 ; Schwab and Bartholdi , 1996	3460
Fawcett and Asher	3460
1999 ; Gimenez y Ribotta et al. , 2002 ; Hu et al. , 2010 ; Kwon and Tetzlaff , 2001 ; Schwab and Bartholdi	3479
1999	3479
Gimenez y Ribotta et al. , 2002 ; Hu et al. , 2010 ; Kwon and Tetzlaff , 2001 ; Schwab and Bartholdi	3485
Gimenez y Ribotta	3485
et al. , 2002 ; Hu et al. , 2010 ; Kwon and Tetzlaff , 2001 ; Schwab and Bartholdi	3503
et al. , 2002	3503
et al.	3503
2002	3511
Hu et al. , 2010	3517
Hu	3517
et al. , 2010	3520
et al.	3520
2010	3528
Kwon and Tetzlaff , 2001	3534
Kwon and Tetzlaff	3534
2001	3553
Schwab and Bartholdi	3559
Schwab	3559
Bartholdi	3570
1996	3581
its irregularity in shape	3599
its irregularity	3599
shape	3619
glial scar removal by surgical or laser resection	3626
glial scar removal	3626
surgical or laser resection	3648
surgical	3648
laser resection	3660
We	3699
a partial removal of the glial scar	3727
a partial removal	3727
the glial scar	3748
the chronically contused rat spinal cord using rose Bengal-dependent phototoxic ablation	3766
the chronically contused rat	3766
spinal cord using	3795
spinal cord	3795
Bengal-dependent phototoxic ablation	3818
the lesion cavity	3882
Bengal	3906
the surface	3939
2 -- 3 layer of astrocytes comprising the glial scar	3951
2	3951
3 layer of astrocytes comprising the glial scar	3953
3 layer	3953
astrocytes comprising the glial scar	3964
astrocytes	3964
the glial scar	3986
Exposure of intracellular	4002
Exposure	4002
Bengal	4033
visible light results	4043
the production of singlet oxygen that is highly harmful to living systems including nucleic acids , proteins , and lipids	4068
the production	4068
singlet oxygen	4086
living systems including nucleic acids , proteins , and lipids	4127
living systems	4127
nucleic acids , proteins , and lipids	4152
nucleic acids	4152
proteins	4167
lipids	4181
glial scar cells	4194
Bengal toxicity	4232
prominent damage to the spared tissue	4260
prominent damage	4260
the spared tissue	4280
the residual axons -LRB- Zhang et al. , 2007 -RRB-	4309
the residual axons	4309
Zhang	4329
et al. , 2007	4335
et al.	4335
2007	4343
We	4350
scar ablation	4376
migration of Schwann cells	4400
migration	4400
Schwann cells	4413
the spared tissue , as determined by the presence of P0 -LRB- myelin glycoprotein P-zero -RRB- - positive myelination	4432
the spared tissue	4432
the presence of P0 -LRB- myelin glycoprotein P-zero -RRB- - positive myelination	4468
the presence	4468
P0 -LRB- myelin glycoprotein P-zero -RRB- - positive myelination	4484
P0	4484
myelin glycoprotein P-zero	4488
positive myelination	4516
The infiltration of Schwann cells	4538
The infiltration	4538
Schwann cells	4558
the elimination of the glial scar as a physical barrier	4604
the elimination	4604
the glial scar as a physical barrier	4623
the glial scar	4623
a physical barrier	4641
These findings	4661
us	4681
the ablation of the glial scar tissue	4704
the ablation	4704
the glial scar tissue	4720
a more appropriate environment for the anatomical recovery	4754
a more appropriate environment	4754
the anatomical recovery	4789
cell/tissue transplantation	4816
a more permissive physical and biochemical environment for axonal growth	4862
a more permissive physical and biochemical environment	4862
axonal growth	4921
functional recovery	4947
the past decade	4975
lamina	4992
propria -LRB- LP -RRB- - derived olfactory ensheathing cells -LRB- OECs -RRB- and lamina propria of olfactory mucosa have attracted much attention from a number of investigators ; they have been considered a leading cell or tissue candidate for transplantation to bridge the gap in spinal cord injury due to their potential reparative properties and function	4999
propria -LRB- LP -RRB-	4999
propria	4999
LP	5008
olfactory ensheathing cells -LRB- OECs -RRB-	5020
olfactory ensheathing cells	5020
OECs	5049
lamina propria of olfactory mucosa	5059
lamina propria	5059
olfactory mucosa	5077
much attention	5109
a number of investigators	5129
a number	5129
investigators	5141
they	5156
a leading cell or tissue candidate	5182
transplantation	5221
the gap in spinal cord injury	5247
the gap	5247
spinal cord injury	5258
their potential reparative properties and function	5284
Boyd et al. , 2005 ; Lima et al. , 2009 ; Lu et al. , 2002 ; Mackay-Sim et al. , 2008 ; Richter et al. , 2005	5336
Boyd	5336
et al. , 2005 ; Lima et al. , 2009 ; Lu et al. , 2002 ; Mackay-Sim et al. , 2008 ; Richter et al. , 2005	5341
et al. , 2005	5341
et al.	5341
2005	5349
Lima et al. , 2009	5355
Lima	5355
et al. , 2009	5360
et al.	5360
2009	5368
Lu et al. , 2002	5374
Lu	5374
et al. , 2002	5377
et al.	5377
2002	5385
Mackay-Sim et al. , 2008	5391
Mackay-Sim	5391
et al. , 2008	5402
et al.	5402
2008	5410
Richter et al. , 2005	5416
Richter	5416
et al. , 2005	5424
et al.	5424
2005	5432
LP OECs	5439
neurotrophins , such as neurotrophin 3 -LRB- NT-3 -RRB- , neurotrophin 4 -LRB- NT-4 -RRB- , nerve growth factor -LRB- NGF -RRB- , brain-derived neurotrophic factor -LRB- BDNF -RRB- , and glial derived neurotrophic factor -LRB- GDNF -RRB- -LRB- Lipson et al. , 2003 -RRB-	5471
neurotrophins	5471
neurotrophin 3 -LRB- NT-3 -RRB- , neurotrophin 4 -LRB- NT-4 -RRB- , nerve growth factor -LRB- NGF -RRB- , brain-derived neurotrophic factor -LRB- BDNF -RRB- , and glial derived neurotrophic factor -LRB- GDNF -RRB- -LRB- Lipson et al. , 2003 -RRB-	5494
neurotrophin 3 -LRB- NT-3 -RRB- , neurotrophin 4 -LRB- NT-4 -RRB- , nerve growth factor -LRB- NGF -RRB- , brain-derived neurotrophic factor -LRB- BDNF -RRB- , and glial	5494
neurotrophin 3 -LRB- NT-3 -RRB-	5494
neurotrophin 3	5494
NT-3	5510
neurotrophin 4 -LRB- NT-4 -RRB-	5517
neurotrophin 4	5517
NT-4	5533
nerve growth factor -LRB- NGF -RRB-	5540
nerve growth factor	5540
NGF	5561
brain-derived neurotrophic factor -LRB- BDNF -RRB-	5567
brain-derived neurotrophic factor	5567
BDNF	5602
glial	5613
neurotrophic factor -LRB- GDNF -RRB- -LRB- Lipson et al. , 2003 -RRB-	5627
neurotrophic factor -LRB- GDNF -RRB-	5627
neurotrophic factor	5627
GDNF	5648
Lipson	5655
et al. , 2003	5662
et al.	5662
2003	5670
Studies	5677
transplanted LP OECs or olfactory bulb -LRB- OB -RRB-	5701
transplanted LP OECs	5701
olfactory bulb -LRB- OB -RRB-	5725
olfactory bulb	5725
OB	5741
OECs	5754
transplantation	5777
the adult mammalian CNS	5798
astrocytes in the animal model of SCI -LRB- Boyd et al. , 2003 ; Lakatos et al. , 2000 ; Richter et al. , 2005 ; Richter and Roskams , 2008 ; Wewetzer et al. , 2002 -RRB-	5843
astrocytes	5843
the animal model of SCI -LRB- Boyd et al. , 2003 ; Lakatos et al. , 2000 ; Richter et al. , 2005 ; Richter and Roskams , 2008 ; Wewetzer et al. , 2002 -RRB-	5857
the animal model	5857
SCI -LRB- Boyd et al. , 2003 ; Lakatos et al. , 2000 ; Richter et al. , 2005 ; Richter and Roskams , 2008 ; Wewetzer et al. , 2002 -RRB-	5877
SCI	5877
Boyd et al. , 2003 ; Lakatos et al. , 2000 ; Richter et al. , 2005 ; Richter and Roskams , 2008 ; Wewetzer et al. , 2002	5882
Boyd	5882
et al. , 2003 ; Lakatos et al. , 2000 ; Richter et al. , 2005 ; Richter and Roskams , 2008 ; Wewetzer et al. , 2002	5887
et al. , 2003	5887
et al.	5887
2003	5895
Lakatos et al. , 2000	5901
Lakatos	5901
et al. , 2000	5909
et al.	5909
2000	5917
Richter et al. , 2005	5923
Richter	5923
et al. , 2005	5931
et al.	5931
2005	5939
Richter and Roskams , 2008	5945
Richter and Roskams	5945
2008	5966
Wewetzer et al. , 2002	5972
Wewetzer	5972
et al. , 2002	5981
et al.	5981
2002	5989
Both LP and OB OEC transplantation	5996
axonal regeneration , remyelination and functional recovery in various models of acute spinal cord injury -LRB- Gorrie et al. , 2010 ; Lindsay et al. , 2010 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Santos-Benito and Ramon-Cueto , 2003 ; Wewetzer et al. , 2002 -RRB-	6060
axonal regeneration , remyelination and functional recovery	6060
various models of acute spinal cord injury -LRB- Gorrie et al. , 2010 ; Lindsay et al. , 2010 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Santos-Benito and Ramon-Cueto , 2003 ; Wewetzer et al. , 2002 -RRB-	6122
various models	6122
acute spinal cord injury -LRB- Gorrie et al. , 2010 ; Lindsay et al. , 2010 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Santos-Benito and Ramon-Cueto , 2003 ; Wewetzer et al. , 2002 -RRB-	6140
acute spinal cord injury	6140
Gorrie et al. , 2010 ; Lindsay et al. , 2010 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Santos-Benito and Ramon-Cueto , 2003 ; Wewetzer et al. , 2002	6166
Gorrie	6166
et al. , 2010 ; Lindsay et al. , 2010 ; Ramon-Cueto et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Santos-Benito and Ramon-Cueto , 2003 ; Wewetzer et al. , 2002	6173
et al. , 2010	6173
et al.	6173
2010	6181
Lindsay et al. , 2010	6187
Lindsay	6187
et al. , 2010	6195
et al.	6195
2010	6203
Ramon-Cueto et al. , 1998	6209
Ramon-Cueto	6209
et al. , 1998	6221
et al.	6221
1998	6229
Ramon-Cueto et al. , 2000	6235
Ramon-Cueto	6235
et al. , 2000	6247
et al.	6247
2000	6255
Santos-Benito and Ramon-Cueto , 2003	6262
Santos-Benito and Ramon-Cueto	6262
2003	6293
Wewetzer et al. , 2002	6299
Wewetzer	6299
et al. , 2002	6308
et al.	6308
2002	6316
LP OECs and OB OECs	6323
LP OECs	6323
OB OECs	6335
many common properties	6349
some differences -LRB- Richter et al. , 2005 ; Rizek and Kawaja , 2006 -RRB-	6377
some differences	6377
Richter	6395
et al. , 2005 ; Rizek and Kawaja , 2006	6403
et al.	6403
2005 ; Rizek and Kawaja	6411
2005	6411
Rizek and Kawaja	6417
2006	6435
further clinical application	6455
it	6484
reparative cells or tissues	6517
an olfactory mucosal biopsy via intranasal endoscopy	6550
an olfactory mucosal biopsy	6550
intranasal endoscopy	6582
the more invasive intracranial approach	6625
an olfactory bulb -LRB- Yamamoto et al. , 2009 -RRB-	6675
an olfactory bulb	6675
Yamamoto	6694
et al. , 2009	6703
et al.	6703
2009	6711
the effects of LP OEC transplantation on a chronic contusion model of rat SCI	6725
the effects	6725
LP OEC transplantation on a chronic contusion model of rat SCI	6740
LP OEC transplantation	6740
a chronic contusion model of rat SCI	6766
a chronic contusion model	6766
rat SCI	6795
Lu et al. , 2002 ; Plant et al. , 2003	6834
Lu	6834
et al. , 2002 ; Plant et al. , 2003	6837
et al. , 2002	6837
et al.	6837
2002	6845
Plant et al. , 2003	6851
Plant	6851
et al. , 2003	6857
et al.	6857
2003	6865
The purpose of this study	6872
The purpose	6872
this study	6887
transplantation of LP / OECs into a chronically contused rat spinal cord after scar ablation	6917
transplantation	6917
LP / OECs into a chronically contused rat spinal cord after scar ablation	6936
LP	6936
OECs into a chronically contused rat spinal cord	6940
OECs	6940
a chronically contused rat spinal cord	6950
scar ablation	6995
the anatomical recovery , axonal regeneration and functional recovery	7023
recovery , axonal regeneration	7038
Results Table 1 -- Animal grouping .	7097
Results Table 1	7097
Results	7097
Table 1	7105
Animal grouping	7115
Animal	7115
grouping	7122
Table 2 -- Primary antibodies used .	7133
Table 2	7133
Primary antibodies used	7143
Primary antibodies	7143
Fig. 1 -- Olfactory lamina propria and cultured OECs .	7169
Fig. 1	7169
Olfactory lamina propria and cultured OECs	7178
Olfactory lamina	7178
propria	7195
OECs	7216
Panel A -LRB- paraffin section , H.E. staining -RRB-	7222
Panel A	7222
paraffin section	7231
H.E. staining	7249
the olfactory mucosa consisting of olfactory epithelium and lamina propria which contains a large number of olfactory nerve fibers -LRB- longitudinal profile -RRB- , blood vessels , and Bowman 's glands -LRB- * -RRB-	7270
the olfactory mucosa	7270
olfactory epithelium and lamina propria which contains a large number of olfactory nerve fibers -LRB- longitudinal profile -RRB- , blood vessels , and Bowman 's glands -LRB- * -RRB-	7305
olfactory epithelium and lamina propria	7305
a large number of olfactory nerve fibers -LRB- longitudinal profile -RRB- , blood vessels , and Bowman 's glands -LRB- * -RRB-	7360
a large number	7360
olfactory nerve fibers -LRB- longitudinal profile -RRB- , blood vessels , and Bowman 's glands -LRB- * -RRB-	7378
olfactory nerve fibers -LRB- longitudinal profile -RRB-	7378
olfactory nerve fibers	7378
longitudinal profile	7402
blood vessels	7425
Bowman 's glands -LRB- * -RRB-	7444
Bowman 's glands	7444
Bowman 's	7444
Panel B	7465
the lamina propria prepared for transplantation -LRB- paraffin section , H.E. staining -RRB- with olfactory epithelium removed	7476
the lamina propria	7476
transplantation -LRB- paraffin section , H.E. staining -RRB-	7508
transplantation	7508
paraffin section	7525
H.E. staining	7543
olfactory epithelium removed	7563
olfactory epithelium	7563
the olfactory nerve fibers -LRB- cross profile -RRB-	7597
the olfactory nerve fibers	7597
cross profile	7625
Panel C	7667
the representative fluorescent image of cultured OECs , which were immunostained , demonstrating expression of p75NTR -LRB- red -RRB- and GFAP -LRB- green -RRB-	7678
the representative fluorescent image	7678
OECs , which were immunostained	7727
OECs	7727
expression of p75NTR -LRB- red -RRB- and GFAP -LRB- green -RRB-	7773
expression	7773
p75NTR -LRB- red -RRB- and GFAP -LRB- green -RRB-	7787
p75NTR	7787
red	7795
GFAP	7804
All nuclei	7818
Hoechst -LRB- blue -RRB-	7847
Hoechst	7847
Scale bars : 100 μm .	7863
Scale bars	7863
100 μm	7875
Fig. 2 -- Scar ablation and LP transplantation .	7884
Fig. 2	7884
Scar ablation and LP transplantation	7893
Glial scars with sharp edge	7931
Glial scars	7931
sharp edge	7948
arrows -LRB- A , H.E. staining ; B , GFAP immunostaining -RRB-	7978
arrows	7978
A , H.E. staining ; B , GFAP immunostaining	7986
A	7986
H.E. staining ; B	7989
H.E. staining	7989
B	8004
GFAP immunostaining	8007
Eight minutes after being injected into the lesion cavity	8029
Eight minutes	8029
the lesion cavity	8069
Bengal -LRB- in pink -RRB-	8093
Bengal	8093
pink	8104
the superficial cells	8126
the morphology of astrocytes -LRB- larger arrows in C -RRB- of the glial scar	8153
the morphology	8153
astrocytes -LRB- larger arrows in C -RRB- of the glial scar	8171
astrocytes -LRB- larger arrows in C -RRB-	8171
astrocytes	8171
larger arrows in C	8183
larger arrows	8183
C	8200
the glial scar	8206
Macrophages -LRB- MΦ -RRB- within the lesion cavity and some other astrocyte-like cells -LRB- small arrows -RRB- underneath the superficial cells	8222
Macrophages -LRB- MΦ -RRB- within the lesion cavity	8222
Macrophages -LRB- MΦ -RRB-	8222
Macrophages	8222
MΦ	8235
the lesion cavity	8246
some other astrocyte-like cells -LRB- small arrows -RRB- underneath the superficial cells	8268
some other astrocyte-like cells -LRB- small arrows -RRB-	8268
some other astrocyte-like cells	8268
small arrows	8301
the superficial cells	8326
different degree	8369
no cell in deeper	8391
no cell	8391
deeper	8402
tissue	8416
the rose Bengal	8438
the rose	8438
Bengal	8447
illumination	8465
Bengal-stained cells of the glial scar	8483
Bengal-stained cells	8483
the glial scar	8507
area between arrows and broken line in D ; H.E. staining	8546
area between arrows	8546
area	8546
arrows	8559
broken line in D ; H.E. staining	8570
broken line in D	8570
broken line	8570
D	8585
H.E. staining	8588
H.E.	8588
staining	8593
a part of damaged glial scar	8604
a part	8604
damaged glial scar	8614
arrowheads and broken line	8659
arrowheads	8659
broken line	8674
the spared tissue being exposed	8701
the spared tissue	8701
The transplanted LP	8734
the lesion cavity close	8772
the spared tissue	8799
Some of the degenerating or demyelinated axons in the spared tissue	8818
Some	8818
the degenerating	8826
axons in the spared tissue	8859
axons	8859
the spared tissue	8868
asterisks -LRB- * -RRB-	8902
asterisks	8902
Scale bars : 0.1 mm -LRB- A , B -RRB- , 0.2 mm -LRB- C , D -RRB- .	8917
Scale bars	8917
0.1 mm -LRB- A , B -RRB- , 0.2 mm -LRB- C , D -RRB-	8929
0.1 mm	8929
A , B	8936
A	8936
B	8939
0.2 mm -LRB- C , D -RRB-	8943
Fig. 3 -- Survival of transplanted GFP-positive cells .	8958
Fig. 3	8958
Survival of transplanted GFP-positive cells	8967
Survival	8967
transplanted GFP-positive cells	8979
Eight weeks	9012
transplantation of GFP-LP	9030
transplantation	9030
GFP-LP	9049
the lesion cavity following the scar ablation	9061
the lesion cavity	9061
the scar ablation	9089
GFP-positive cells -LRB- green in A , sagittal cryosection -RRB-	9108
GFP-positive cells	9108
green in A , sagittal cryosection	9128
green in A	9128
sagittal cryosection	9140
the spared tissue marked by GFAP -LRB- red -RRB-	9203
the spared tissue	9203
GFAP -LRB- red -RRB-	9231
GFAP	9231
red	9237
higher magnification	9249
most of GFP-positive cells	9271
most	9271
GFP-positive cells	9279
their orientation parallel	9311
the longitudinal axis of the spinal cord	9341
the longitudinal axis	9341
the spinal cord	9366
the NF-positive axons -LRB- red in B , pointed by arrows -RRB-	9420
the NF-positive axons	9420
red in B , pointed by arrows	9443
red	9443
B , pointed by arrows	9450
B	9450
arrows	9464
Scale bars : 0.5 mm -LRB- A -RRB- , 0.1 mm -LRB- B -RRB- .	9473
Scale bars	9473
0.5 mm -LRB- A -RRB- , 0.1 mm -LRB- B -RRB-	9485
0.5 mm	9485
A	9492
0.1 mm -LRB- B -RRB-	9496
B	9503
Fig. 4 -- Tissue repair after scar ablation and transplantation .	9508
Fig. 4	9508
Tissue repair after scar ablation and transplantation	9517
Tissue repair	9517
scar ablation and transplantation	9537
A , B , C , D and E	9572
A , B , C , D	9572
E	9587
cross sections at the injury epicenter from different groups	9593
cross sections	9593
the injury epicenter from different groups	9611
the injury epicenter	9611
different groups	9637
the others in the same rows	9658
the others	9658
the same rows	9672
their local magnifications	9690
Panels in the left and middle columns	9732
Panels	9732
the left and middle columns	9742
the left	9742
middle columns	9755
H.E. staining	9774
those in the right column	9794
those	9794
the right column	9803
GFAP immunostaining	9824
tissue , repaired tissue and lesion cavity	9852
tissue	9852
tissue and lesion cavity	9869
the glial scars with sharp edge	9918
the glial scars	9918
sharp edge	9939
arrows	9969
the last two groups -LRB- D and E rows -RRB-	9980
the last two groups	9980
D and E rows	10001
D	10001
E rows	10007
development of repaired tissue , disappearance of the lesion cavities , integration of repaired tissue with spared tissue -LRB- D ′ , E ′ -RRB- , and disappearance of glial scar -LRB- D ″ , E ″ -RRB-	10016
development of repaired tissue	10016
development	10016
repaired tissue	10031
disappearance of the lesion cavities , integration of repaired tissue with spared tissue -LRB- D ′ , E ′ -RRB-	10048
disappearance	10048
the lesion cavities , integration of repaired tissue with spared tissue -LRB- D ′ , E ′ -RRB-	10065
the lesion cavities	10065
integration of repaired tissue with spared tissue -LRB- D ′ , E ′ -RRB-	10086
integration	10086
repaired tissue with spared tissue -LRB- D ′ , E ′ -RRB-	10101
repaired tissue	10101
spared tissue -LRB- D ′ , E ′ -RRB-	10122
spared tissue	10122
D ′	10137
E ′	10141
disappearance of glial scar -LRB- D ″ , E ″ -RRB-	10150
disappearance	10150
glial scar -LRB- D ″ , E ″ -RRB-	10167
glial scar	10167
D ″	10179
E ″	10183
SCI : spinal cord injury ; SA : scar ablation ; LP : LP transplantation ; OEC : OEC transplantation .	10215
SCI	10215
spinal cord injury	10220
spinal cord	10220
injury	10232
SA : scar ablation	10240
SA	10240
scar ablation	10244
LP : LP transplantation	10259
LP	10259
LP transplantation	10263
OEC : OEC transplantation	10283
OEC	10283
OEC transplantation	10288
ST	10309
tissue ; DR : dorsal root ; Scale bars : 0.5 mm -LRB- left column -RRB- , 50 μm -LRB- all others -RRB-	10320
tissue	10320
DR	10328
dorsal root	10332
Scale bars	10345
0.5 mm -LRB- left column -RRB- , 50 μm -LRB- all others -RRB-	10357
0.5 mm	10357
left column	10364
50 μm -LRB- all others -RRB-	10378
50 μm	10378
all others	10385
Fig. 5 -- Quantitative analysis of tissue repair .	10399
Fig. 5	10399
Quantitative analysis of tissue repair	10408
Quantitative analysis	10408
tissue repair	10433
The percentages of spared tissue , repaired tissue and lesion cavity to the whole area of a cross section at the injury epicenter in each group	10448
The percentages	10448
spared tissue , repaired tissue and lesion cavity to the whole area of a cross section at the injury epicenter in each group	10467
spared tissue	10467
tissue and lesion cavity	10491
the whole area of a cross section	10519
the whole area	10519
a cross section	10537
the injury epicenter in each group	10556
the injury epicenter	10556
each group	10580
SEM	10607
Changes between Groups SCI-6w and SCI-22w as well as between Group SCI-22w and Group SCI+SA	10613
Changes	10613
Groups SCI-6w and SCI-22w as well as between Group SCI-22w and Group SCI+SA	10629
Groups SCI-6w and SCI-22w	10629
between Group SCI-22w and Group SCI+SA	10666
Group SCI-22w and Group SCI+SA	10674
the developments of repaired tissue and the reduction of lesion cavities	10733
the developments	10733
repaired tissue and the reduction of lesion cavities	10753
repaired tissue	10753
the reduction of lesion cavities	10773
the reduction	10773
lesion cavities	10790
p	10841
0.01	10843
groups with transplantations	10852
groups	10852
transplantations	10864
the SCI-22w control group	10900
SCI : spinal cord injury ; 6w/22w : 6 or 22 weeks after SCI ; SA : scar ablation ; LP : LP transplantation ; OEC : OEC transplantation .	10927
SCI	10927
spinal cord injury ; 6w/22w	10932
spinal cord injury	10932
6w/22w	10952
6 or 22 weeks after SCI ; SA : scar ablation ; LP : LP transplantation ; OEC : OEC transplantation	10960
6 or 22 weeks	10960
SCI ; SA : scar ablation ; LP : LP transplantation ; OEC : OEC transplantation	10980
SCI	10980
SA	10985
scar ablation	10989
LP	11004
LP transplantation	11008
OEC	11028
OEC transplantation	11033
Fig. 7 -- Quantitative analysis of P0-positive myelination .	11055
Fig. 7	11055
Quantitative analysis of P0-positive myelination	11064
Quantitative analysis	11064
P0-positive myelination	11089
the cross sections	11117
the P0-positive myelin sheaths	11137
the repaired tissue , lesion cavity	11184
the repaired tissue	11184
lesion cavity	11205
tissue	11231
the injury epicenter	11241
The average number -LRB- mean ± SEM -RRB- of P0-positive myelin sheaths and the comparison among groups	11263
The average number -LRB- mean ± SEM -RRB-	11263
The average number	11263
mean ± SEM	11283
P0-positive myelin sheaths and the comparison among groups	11297
P0-positive myelin sheaths	11297
the comparison among groups	11328
the comparison	11328
groups	11349
p < 0.05 ; ** : p < 0.01	11370
p	11370
0.05 ; ** : p <	11372
0.05	11372
p	11382
0.01	11384
SCI : spinal cord injury ; LP : LP transplantation ; OEC : OEC transplantation ; SA : scar ablation .	11390
SCI	11390
spinal cord injury	11395
spinal cord	11395
injury	11407
LP : LP transplantation	11415
LP	11415
LP transplantation	11419
OEC : OEC transplantation	11439
OEC	11439
OEC transplantation	11444
SA : scar ablation	11465
SA	11465
scar ablation	11469
the first two groups	11494
6 weeks or 22 weeks	11519
6 weeks	11519
22 weeks	11530
SCI	11545
other groups	11550
all 16 weeks after secondary surgeries , i.e. , 22 weeks after SCI	11567
all 16 weeks after secondary surgeries , i.e. ,	11567
all 16 weeks after secondary surgeries	11567
all 16 weeks	11567
secondary surgeries	11586
22 weeks	11613
SCI	11628
Fig. 6 -- P0-positive myelination .	11634
Fig. 6	11634
P0-positive myelination	11643
Representative photomicrographs of P0 immunostaining from the injury alone control group -LRB- A -RRB- and the full treatment group -LRB- B -RRB-	11668
Representative photomicrographs	11668
P0 immunostaining from the injury alone control group -LRB- A -RRB- and the full treatment group -LRB- B -RRB-	11703
P0 immunostaining	11703
the injury alone control group -LRB- A -RRB- and the full treatment group -LRB- B -RRB-	11726
the injury	11726
control group -LRB- A -RRB- and the full treatment group -LRB- B -RRB-	11743
control group -LRB- A -RRB-	11743
control group	11743
A	11758
the full treatment group -LRB- B -RRB-	11765
the full treatment group	11765
B	11791
the distribution of P0-positive myelin sheaths at the injury site	11805
the distribution	11805
P0-positive myelin sheaths at the injury site	11825
P0-positive myelin sheaths	11825
the injury site	11855
A ′ and B ′	11872
local magnifications of A and B	11886
local magnifications	11886
A and B	11910
The myelin sheaths	11933
dark brown in color	11964
dark brown	11964
color	11978
small circles or dots -LRB- arrowheads in insert , which is local magnification of B ′ -RRB-	11998
small circles or dots	11998
arrowheads in insert , which is local magnification of B ′	12021
arrowheads	12021
insert , which is local magnification of B ′	12035
insert	12035
local magnification of B ′	12052
local magnification	12052
B ′	12075
The P0-positive myelin sheaths	12080
the repaired tissue , lesion cavity	12131
the repaired tissue	12131
lesion cavity	12152
tissue	12185
the dorsal roots -LRB- DR -RRB- and ventral roots -LRB- VR -RRB-	12204
the dorsal roots	12204
DR	12222
ventral roots	12230
VR	12245
The average numbers of P0-positive myelin sheaths in individual groups	12250
The average numbers	12250
P0-positive myelin sheaths in individual groups	12273
P0-positive myelin sheaths	12273
individual groups	12303
Fig. 7	12338
SCI : spinal cord injury ; SA : scar ablation ; LP : LP transplantation ; OEC : OEC transplantation .	12346
SCI	12346
spinal cord injury	12351
spinal cord	12351
injury	12363
SA : scar ablation	12371
SA	12371
scar ablation	12375
LP : LP transplantation	12390
LP	12390
LP transplantation	12394
OEC : OEC transplantation	12414
OEC	12414
OEC transplantation	12419
Scale bars : 0.5 mm -LRB- A , B -RRB- , 0.1 mm -LRB- A ′ , B ′ -RRB- , 20 μm -LRB- insert -RRB- .	12440
Scale bars	12440
0.5 mm -LRB- A , B -RRB- , 0.1 mm -LRB- A ′ , B ′ -RRB- , 20 μm -LRB- insert -RRB-	12452
0.5 mm -LRB- A , B -RRB-	12452
A , B	12459
A	12459
B	12462
0.1 mm -LRB- A ′ , B ′ -RRB-	12466
A ′ , B ′	12473
A ′	12473
B ′	12477
20 μm -LRB- insert -RRB-	12482
insert	12489
Fig. 8 -- Locomotor outcome .	12499
Fig. 8	12499
Locomotor outcome	12508
Functional recovery after transplantation	12527
Functional recovery	12527
transplantation	12553
BBB open field scale and the BBB scores	12588
BBB open field scale	12588
the BBB scores	12613
SEM	12634
different groups are shown	12644
different groups	12644
There	12672
no significant difference	12681
any two groups or self	12722
any two groups	12722
self	12740
treatments in any individual group -LRB- p > 0.05 -RRB-	12777
treatments	12777
any individual group -LRB- p > 0.05 -RRB-	12791
any individual group	12791
p > 0.05	12813
p	12813
> 0.05	12814
>	12814
0.05	12815
SCI : spinal cord injury ; SA : scar ablation ; LP : LP transplantation ; OEC : OEC transplantation ; 6/0w : 6 weeks after SCI , i.e. just before the transplantation ; 22/16 : 22 weeks after SCI , i.e. 16 weeks after secondary surgeries .	12822
SCI	12822
spinal cord injury	12827
spinal cord	12827
injury	12839
SA : scar ablation	12847
SA	12847
scar ablation	12851
LP : LP transplantation	12866
LP	12866
LP transplantation	12870
OEC : OEC transplantation	12890
OEC	12890
OEC transplantation	12895
6/0w : 6 weeks after SCI , i.e. just before the transplantation ; 22/16 : 22 weeks after SCI , i.e. 16 weeks after secondary surgeries	12916
6/0w	12916
: 6 weeks after SCI , i.e. just before the transplantation ; 22/16 : 22 weeks after SCI , i.e. 16 weeks after secondary surgeries	12920
6 weeks after SCI	12922
6 weeks	12922
SCI	12936
just before the transplantation ; 22/16 : 22 weeks after SCI , i.e. 16 weeks after secondary surgeries	12946
the transplantation ; 22/16 : 22 weeks after SCI	12958
the transplantation ; 22/16	12958
the transplantation	12958
22/16	12979
22 weeks after SCI	12986
22 weeks	12986
SCI	13001
16 weeks after secondary surgeries	13011
16 weeks	13011
secondary surgeries	13026
2.1	13049
Confirmation of scar ablation and LP transplantation The glial scar	13054
Confirmation	13054
scar ablation and LP transplantation The glial scar	13070
scar ablation and LP transplantation	13070
The glial scar	13107
the inner edge of the spared tissue , consisting of 2 or 3 layers of GFAP-positive cells with a smooth free surface , facing the lesion cavity	13137
the inner edge	13137
the spared tissue , consisting of 2 or 3 layers of GFAP-positive cells with a smooth free surface , facing the lesion cavity	13155
the spared tissue	13155
of 2 or 3 layers of GFAP-positive cells	13185
of 2 or 3 layers	13185
GFAP-positive cells	13205
a smooth free surface	13230
the lesion cavity	13260
there	13283
no clear border between the glial scar	13292
no clear border	13292
the glial scar	13316
tissue -LRB- Fig. 2A and B ; Fig. 4A -RRB-	13342
tissue	13342
Fig. 2A and B ; Fig. 4A	13350
Fig. 2A and B	13350
Fig. 4A	13365
Eight minutes	13375
the lesion cavity	13415
the	13434
Bengal	13443
the cell body and processes of the superficial cells	13478
the cell body	13478
processes of the superficial cells	13496
processes	13496
the superficial cells	13509
the morphology of astrocytes -LRB- Fig. 2C -RRB- , which constitute the scar tissue	13536
the morphology	13536
astrocytes -LRB- Fig. 2C -RRB- , which constitute the scar tissue	13554
astrocytes -LRB- Fig. 2C -RRB-	13554
astrocytes	13554
Fig. 2C	13566
the scar tissue	13593
Collateral cells within the deeper portion of the spared tissue	13610
Collateral cells	13610
the deeper portion of the spared tissue	13634
the deeper portion	13634
the spared tissue	13656
the	13694
illumination	13709
Bengal-stained cells of the glial scar	13728
Bengal-stained cells	13728
the glial scar	13752
phototoxicity	13782
the separation or disruption of damaged glial scar from the spared tissue -LRB- Fig. 2D -RRB-	13810
the separation or disruption	13810
damaged glial scar from the spared tissue -LRB- Fig. 2D -RRB-	13842
damaged glial scar	13842
the spared tissue -LRB- Fig. 2D -RRB-	13866
the spared tissue	13866
Fig. 2D	13885
The transplanted LP	13895
the lesion cavity close	13948
the spared tissue -LRB- Fig. 2D -RRB-	13975
the spared tissue	13975
Fig. 2D	13994
2.2	14004
Survival of transplanted GFP-LP and relationwith axons Eight weeks after scar ablation and transplantation of GFP-LP into the lesion cavity , the GFP-positive cells	14009
Survival	14009
transplanted GFP-LP and relationwith axons Eight weeks after scar ablation and transplantation of GFP-LP into the lesion cavity , the GFP-positive cells	14021
transplanted GFP-LP and relationwith axons	14021
Eight weeks	14064
scar ablation and transplantation of GFP-LP into the lesion cavity , the GFP-positive cells	14082
scar ablation and transplantation	14082
GFP-LP into the lesion cavity , the GFP-positive cells	14119
GFP-LP	14119
the lesion cavity , the GFP-positive cells	14131
the lesion cavity	14131
the GFP-positive cells	14150
the injury epicenter	14194
They	14216
the lesion cavity	14247
the host spared tissue which was labeled by the GFAP marker -LRB- Fig. 3A -RRB-	14283
the host	14283
tissue which was labeled by the GFAP marker -LRB- Fig. 3A -RRB-	14299
tissue	14299
the GFAP marker -LRB- Fig. 3A -RRB-	14327
the GFAP marker	14327
Fig. 3A	14344
addition	14357
the orientation of GFP-positive cells	14367
the orientation	14367
GFP-positive cells	14386
a nonparallel pattern in relation	14424
a nonparallel pattern	14424
relation	14449
the longitudinal axis of the spinal cord	14461
the longitudinal axis	14461
the spinal cord	14486
the axons	14506
the GFP-positive cells -LRB- Fig. 3B -RRB-	14556
the GFP-positive cells	14556
Fig. 3B	14580
The observation	14590
the survival of cells	14616
the survival	14616
cells	14632
transplanted LP , consistent with other recent observation of the survival of transplanted OECs	14643
transplanted LP	14643
other recent observation of the survival of transplanted OECs	14676
other recent observation	14676
the survival of transplanted OECs	14704
the survival	14704
transplanted OECs	14720
a lesion cavity of rat contused spinal cord -LRB- Li et al. , 2010 -RRB-	14743
a lesion cavity	14743
rat contused spinal cord -LRB- Li et al. , 2010 -RRB-	14762
rat	14762
spinal cord -LRB- Li et al. , 2010 -RRB-	14775
spinal cord	14775
Li	14788
et al. , 2010	14791
et al.	14791
2010	14799
2.3	14806
Tissue repairing after scar ablation and transplantation Similar to the results seen 6 weeks after contusion injury -LRB- Fig. 2A and B -RRB- , in the injury control animals 22 weeks after SCI a clear lesion cavity	14811
Tissue	14811
scar ablation and transplantation Similar	14834
scar ablation	14834
transplantation Similar	14852
the results seen 6 weeks after contusion injury -LRB- Fig. 2A and B -RRB- , in the injury control animals 22 weeks after SCI a clear lesion cavity	14879
the results	14879
6 weeks	14896
contusion injury	14910
Fig. 2A and B	14928
Fig. 2A	14928
B	14940
the injury control animals 22 weeks after SCI a clear lesion cavity	14947
the injury control animals	14947
22 weeks	14974
SCI	14989
a clear lesion cavity	14993
the injury site	15036
the spared tissue by the glial scar	15075
the spared tissue	15075
the glial scar	15096
The morphology of glial scar and the endogenous repaired tissue in size at the injury epicenter	15112
The morphology	15112
glial scar and the endogenous repaired tissue in size at the injury epicenter	15130
glial scar	15130
the endogenous repaired tissue in size at the injury epicenter	15145
the endogenous	15145
tissue in size	15169
tissue	15169
size	15179
the injury epicenter	15187
significant change -LRB- Fig. 4A , A ′ , and A ″ ; Fig. 5 -RRB-	15222
significant change	15222
Fig. 4A , A ′ , and A ″ ; Fig. 5	15242
Fig. 4A	15242
A ′	15251
A ″ ; Fig. 5	15259
A ″	15259
Fig. 5	15263
the contrary	15275
the animals that received scar ablation in conjunction with transplantation of either LP or LP plus OEC	15292
the animals	15292
scar ablation	15318
conjunction	15335
transplantation of either LP or LP plus OEC	15352
transplantation	15352
either LP or LP	15371
LP	15378
LP	15384
OEC	15392
the repaired tissue	15397
the lesion cavity	15446
marked reduction	15478
even disappearance of the lesion cavity	15495
even disappearance	15495
the lesion cavity	15517
fact	15539
transplanted LP	15545
the repaired tissue at the injury site	15606
the repaired tissue	15606
the injury site	15629
numerous Schwann	15652
cell-like , young cells	15669
the transplanted tissue or cells	15723
the transplanted tissue	15723
cells	15750
a part of the repaired tissue	15801
a part	15801
the repaired tissue	15811
no apparent border	15850
the repaired tissue	15890
tissue	15921
the repaired tissue	15945
the spared tissue	15995
addition	16017
the typical glial scar detected by GFAP immunostaining	16027
the typical glial scar	16027
GFAP immunostaining	16062
Fig. 4D -- E ″	16097
Fig. 4D	16097
E ″	16105
the injury control group	16120
the group of LP transplantation	16151
the group	16151
LP transplantation	16164
scar ablation	16191
this further	16206
the merging of two different tissues	16228
the merging	16228
two different tissues	16243
animals	16269
LP or LP/OEC transplantation	16287
scar ablation	16324
the repaired tissue	16339
16 weeks	16381
transplantation	16396
it	16417
the spared tissue by the glial scar and the lesion cavity -LRB- Fig. 4B , B ′ , and B ″ ; Fig. 5 -RRB-	16438
the spared tissue	16438
the glial scar and the lesion cavity -LRB- Fig. 4B , B ′ , and B ″ ; Fig. 5 -RRB-	16459
the glial scar	16459
the lesion cavity -LRB- Fig. 4B , B ′ , and B ″ ; Fig. 5 -RRB-	16478
the lesion cavity	16478
Fig. 4B , B ′ , and B ″ ; Fig. 5	16497
Fig. 4B	16497
B ′	16506
B ″ ; Fig. 5	16514
B ″	16514
Fig. 5	16518
Quantitative analysis about the changes of repaired tissue and lesion cavity in size	16527
Quantitative analysis	16527
the changes of repaired tissue and lesion cavity in size	16555
the changes	16555
repaired tissue and lesion cavity in size	16570
repaired tissue and lesion cavity	16570
size	16607
Fig. 5	16624
There	16632
no prominent changes	16642
tissue and lesion cavity in size in a long period of time	16673
tissue and lesion cavity	16673
size in a long period of time	16701
size	16701
a long period of time	16709
a long period	16709
time	16726
injury	16737
rats	16747
no treatment -LRB- SCI-6w vs. SCI-22w -RRB-	16760
no treatment	16760
SCI-6w vs. SCI-22w	16774
SCI-6w	16774
SCI-22w	16785
the expansion of repaired tissue and the reduction of lesion cavities in size	16804
the expansion	16804
repaired tissue and the reduction of lesion cavities in size	16821
repaired tissue	16821
the reduction of lesion cavities in size	16841
the reduction	16841
lesion cavities in size	16858
lesion cavities	16858
size	16877
p < 0.01	16913
p	16913
< 0.01	16914
<	16914
0.01	16915
groups with transplantations	16924
groups	16924
transplantations	16936
the injury	16972
only control group -LRB- SCI-22w -RRB-	16983
only control group	16983
SCI-22w	17003
2.4	17013
Prevention of scar reformation by transplantation	17018
Prevention	17018
scar reformation by transplantation	17032
scar reformation	17032
transplantation	17052
scar ablation without LP or OEC transplantation , the endogenous repaired tissue and lesion cavity did not appear obvious change in size	17074
scar ablation	17074
LP or OEC transplantation , the endogenous repaired tissue and lesion cavity did not appear obvious change in size	17096
LP or OEC transplantation	17096
the endogenous repaired tissue and lesion cavity did not appear obvious change in size	17123
the endogenous	17123
tissue and lesion cavity	17147
obvious change	17187
size	17205
Fig. 5	17211
the number of P0-positive myelin sheaths -LRB- Fig. 7 -RRB- and the BBB scores -LRB- Fig. 8 -RRB-	17220
the number	17220
P0-positive myelin sheaths -LRB- Fig. 7 -RRB- and the BBB scores -LRB- Fig. 8 -RRB-	17234
P0-positive myelin sheaths	17234
Fig. 7	17262
the BBB scores	17274
Fig. 8	17290
those seen 6 weeks after injury	17350
those	17350
6 weeks	17361
injury	17375
the surviving astrocytes at the deeper portion of the glial scar	17392
the surviving astrocytes	17392
the deeper portion of the glial scar	17420
the deeper portion	17420
the glial scar	17442
the inner edge of the spared tissue	17485
the inner edge	17485
the spared tissue	17503
the reformation of the glial scar -LRB- Fig. 4C ′ -RRB-	17541
the reformation of the glial scar	17541
the reformation	17541
the glial scar	17560
Fig. 4C ′	17576
Similar to the original glial scar -LRB- Fig. 2A and B -RRB- , the newly formed glial scar	17587
Similar	17587
the original glial scar -LRB- Fig. 2A and B -RRB- , the newly formed glial scar	17598
the original glial scar -LRB- Fig. 2A and B -RRB-	17598
the original glial scar	17598
Fig. 2A and B	17623
Fig. 2A	17623
B	17635
the newly formed glial scar	17639
the lesion cavity	17673
strong GFAP-immunoreactivity	17701
the spared tissue -LRB- Fig. 4C ″ -RRB-	17741
the spared tissue	17741
Fig. 4C ″	17760
Fig.	17760
4C ″	17765
The glial scar	17771
dense GFAP immunostaining 22 weeks	17812
dense GFAP immunostaining	17812
22 weeks	17838
contusion injury -LRB- Fig. 4A ″ -RRB- , similar to what was observed before	17853
contusion injury -LRB- Fig. 4A ″ -RRB-	17853
contusion injury	17853
Fig. 4A ″	17871
rats with LP transplantation but no scar ablation	17922
rats	17922
LP transplantation but no scar ablation	17932
LP transplantation	17932
no scar ablation	17955
the glial scar	17973
prominent modification	18001
16 weeks	18024
transplantation	18039
Fig. 4B ″	18056
Fig.	18056
4B ″	18061
the animals with scar ablation and LP or LP plus OEC transplantation	18078
the animals with scar ablation and LP	18078
the animals	18078
scar ablation and LP	18095
LP plus OEC transplantation	18119
LP	18119
OEC transplantation	18127
the glial scar in proximity to where it occurred before being ablated disappeared and its characteristic sharp , densely-stained GFAP profile	18148
the glial scar	18148
proximity to where it occurred before being ablated disappeared and its characteristic sharp , densely-stained GFAP profile	18166
proximity	18166
where it occurred before being ablated disappeared and its characteristic sharp , densely-stained GFAP profile	18179
it	18185
its characteristic sharp , densely-stained GFAP profile	18234
a dentate , irregular or reticular appearance of GFAP immunoreactivity -LRB- Fig. 4D ″ and E ″ -RRB- ,	18310
a dentate	18310
irregular or reticular appearance of GFAP immunoreactivity -LRB- Fig. 4D ″ and E ″ -RRB-	18321
irregular or reticular appearance	18321
GFAP immunoreactivity -LRB- Fig. 4D ″ and E ″ -RRB-	18358
GFAP immunoreactivity	18358
Fig. 4D ″ and E ″	18381
Fig. 4D ″	18381
E ″	18394
the glial scar	18413
2.5	18446
Increase in P0-positive myelination after combination treatments	18451
Increase	18451
P0-positive myelination after combination treatments	18463
P0-positive myelination	18463
combination treatments	18493
our previous observation , Schwann cells and Schwann cell-formed myelin sheaths	18529
our previous observation	18529
Schwann cells	18555
Schwann cell-formed myelin sheaths	18573
the endogenous repaired tissue -LRB- previously called connective tissue scar -RRB- two weeks	18627
the endogenous repaired tissue -LRB- previously called connective tissue scar -RRB-	18627
the endogenous repaired tissue	18627
connective tissue scar	18677
two weeks	18701
contusion injury -LRB- Zhang et al. , 2005 -RRB-	18717
contusion injury	18717
Zhang	18735
et al. , 2005	18741
et al.	18741
2005	18749
Some of the Schwann cells	18756
Some	18756
the Schwann cells	18764
the repaired tissue to the spared tissue	18799
the repaired tissue	18799
the spared tissue	18822
the trabeculae between the spared tissue and the repaired tissue	18857
the trabeculae	18857
the spared tissue and the repaired tissue	18880
the spared tissue	18880
the repaired tissue	18902
some	18926
the ventral root	18950
the axons	18981
the spared tissue of ventral portion of the cord	18994
the spared tissue	18994
ventral portion of the cord	19015
ventral portion	19015
the cord	19034
this study	19047
P0-positive myelination possibly formed by the host Schwann cells	19059
P0-positive myelination	19059
the host Schwann cells	19102
the repaired tissue , lesion cavity	19139
the repaired tissue	19139
lesion cavity	19160
tissue -LRB- Fig. 6 -RRB-	19186
tissue	19186
Fig. 6	19194
These myelinated fibers	19203
regenerating axons	19239
axons	19274
P0 - positive myelin sheaths in the repaired tissue	19281
P0	19281
positive myelin sheaths in the repaired tissue	19285
positive myelin sheaths	19285
the repaired tissue	19312
both	19344
axons	19374
Quantitative analysis of P0-positive myelination	19381
Quantitative analysis	19381
P0-positive myelination	19406
Fig. 7	19442
injury alone control rats	19453
injury	19453
alone control rats	19460
the number of P0-positive myelin sheaths	19479
the number	19479
P0-positive myelin sheaths	19493
a significant change at the last 16 weeks -LRB- SCI 22w : 1750 ± 254 , n = 6 -RRB- compared with that found 6 weeks after injury -LRB- SCI 6w : 1966 ± 433 , n = 5 -RRB-	19533
a significant change	19533
the last 16 weeks -LRB- SCI 22w : 1750 ± 254 , n = 6 -RRB- compared with that found 6 weeks after injury -LRB- SCI 6w : 1966 ± 433 , n = 5 -RRB-	19557
the last 16 weeks -LRB- SCI 22w : 1750 ± 254 , n = 6 -RRB-	19557
the last 16 weeks	19557
SCI 22w : 1750 ± 254 , n = 6	19576
SCI 22w	19576
1750 ± 254 , n = 6	19585
1750 ±	19585
254 , n = 6	19590
254	19590
n = 6	19595
n	19595
6	19597
that found 6 weeks after injury -LRB- SCI 6w : 1966 ± 433 , n = 5 -RRB-	19614
that	19614
6 weeks	19625
injury	19639
SCI 6w : 1966 ± 433 , n = 5	19647
SCI 6w	19647
1966 ± 433 , n = 5	19655
1966 ±	19655
433 , n = 5	19660
433	19660
n = 5	19665
n	19665
5	19667
The number of P0-positive myelin sheaths	19671
The number	19671
P0-positive myelin sheaths	19685
slightly in rats with LP -LRB- SCI+LP : 2268 ± 385 , n = 4 -RRB- or LP plus OEC -LRB- SCI+LP+OEC : 2584 ± 198 , n = 5 -RRB- transplantation	19722
rats with LP -LRB- SCI+LP : 2268 ± 385 , n = 4 -RRB- or LP plus OEC -LRB- SCI+LP+OEC : 2584 ± 198 , n = 5 -RRB-	19734
rats with LP -LRB- SCI+LP : 2268 ± 385 , n = 4 -RRB-	19734
rats	19734
LP -LRB- SCI+LP : 2268 ± 385 , n = 4 -RRB-	19744
LP	19744
SCI+LP : 2268 ± 385 , n = 4	19748
SCI+LP	19748
2268 ± 385 , n = 4	19756
2268 ±	19756
385 , n = 4	19761
385	19761
n = 4	19766
n	19766
4	19768
LP plus OEC -LRB- SCI+LP+OEC : 2584 ± 198 , n = 5 -RRB-	19774
LP	19774
OEC -LRB- SCI+LP+OEC : 2584 ± 198 , n = 5 -RRB-	19782
OEC	19782
SCI+LP+OEC : 2584 ± 198 , n = 5	19787
SCI+LP+OEC	19787
2584 ± 198 , n = 5	19799
2584 ±	19799
198 , n = 5	19805
198	19805
n = 5	19810
n	19810
5	19812
scar ablation	19839
the difference	19863
the SCI control animals	19931
Rats subjected to scar ablation	19956
Rats	19956
scar ablation	19974
an increase in number of P0-positive myelin sheaths -LRB- SCI+SA : 1759 ± 215 , n = 6 -RRB-	20007
an increase	20007
number of P0-positive myelin sheaths -LRB- SCI+SA : 1759 ± 215 , n = 6 -RRB-	20022
number	20022
P0-positive myelin sheaths -LRB- SCI+SA : 1759 ± 215 , n = 6 -RRB-	20032
P0-positive myelin sheaths	20032
SCI+SA : 1759 ± 215 , n = 6	20060
SCI+SA	20060
1759 ± 215 , n = 6	20068
1759 ±	20068
215 , n = 6	20073
215	20073
n = 6	20078
n	20078
6	20080
injury	20102
alone control rats	20109
The group that received scar ablation and LP transplantation showedmore P0-positivemyelin sheaths -LRB- SCI+SA+LP : 3043 ± 404 , n = 8 -RRB- with a significant difference when compared with the control animals .	20129
The group that received scar ablation and LP transplantation showedmore P0-positivemyelin sheaths -LRB- SCI+SA+LP : 3043 ± 404 , n = 8 -RRB-	20129
The group	20129
scar ablation and LP transplantation showedmore P0-positivemyelin sheaths	20153
SCI+SA+LP : 3043 ± 404 , n = 8	20228
SCI+SA+LP	20228
3043 ± 404 , n = 8	20239
3043 ±	20239
404 , n = 8	20244
404	20244
n = 8	20249
n	20249
8	20251
a significant difference when	20259
a significant difference	20259
the control animals	20303
A further increase in the number of P0-positive myelin sheaths	20324
A further increase	20324
the number of P0-positive myelin sheaths	20346
the number	20346
P0-positive myelin sheaths	20360
the group receiving scar ablation andtransplantation of both LP and OECs -LRB- SCI+SA+LP+OEC : 4001 ± 569 , n = 7 -RRB-	20403
the group	20403
scar ablation andtransplantation of both LP and OECs -LRB- SCI+SA+LP+OEC : 4001 ± 569 , n = 7 -RRB-	20423
scar ablation andtransplantation	20423
both LP and OECs -LRB- SCI+SA+LP+OEC : 4001 ± 569 , n = 7 -RRB-	20459
both LP and OECs	20459
SCI+SA+LP+OEC : 4001 ± 569 , n = 7	20477
SCI+SA+LP+OEC	20477
4001 ± 569 , n = 7	20492
4001 ±	20492
569 , n = 7	20497
569	20497
n = 7	20502
n	20502
7	20504
2.6	20508
Locomotor outcome of functional recovery Locomotor functional recovery after SCI and the indicated interventions	20513
Locomotor outcome of functional recovery Locomotor functional recovery after SCI	20513
Locomotor outcome	20513
functional recovery Locomotor functional recovery	20534
SCI	20590
the indicated interventions	20598
the BBB open field scale -LRB- Basso et al. , 1995 ; 1996 -RRB-	20647
the BBB open field scale	20647
Basso	20673
et al. , 1995 ; 1996	20679
et al.	20679
1995 ; 1996	20687
Control animals receiving contusion injury only	20700
Control animals	20700
contusion injury	20726
a functional level of that maintained almost unchanged during the final 16 weeks of observation -LRB- SCI control : 9.35 ± 0.21 to 9.45 ± 0.31 , n = 10 -RRB- -LRB- Fig. 8 -RRB-	20762
a functional level	20762
the final 16 weeks of observation	20824
the final 16 weeks	20824
observation	20846
SCI control : 9.35 ± 0.21	20859
SCI control	20859
9.35 ± 0.21	20872
9.35	20872
0.21	20877
9.45 ± 0.31 , n = 10	20885
9.45 ± 0.31	20885
n = 10	20896
n	20896
10	20898
Fig. 8	20903
Animals receiving LP transplantation	20912
Animals	20912
LP transplantation	20930
BBB scores that started off at 9.27 ± 0.27 before transplantation and ended at 9.73 ± 0	20977
BBB scores	20977
9.27 ± 0.27	21008
transplantation	21025
9.73 ±	21054
0	21059
36 sixteen weeks after transplantation -LRB- n = 11 -RRB- .	21062
36	21062
sixteen weeks	21065
transplantation -LRB- n = 11 -RRB-	21085
transplantation	21085
n	21102
11	21104
Animals receiving LP/OEC transplantation without scar ablation	21109
Animals	21109
LP/OEC transplantation	21127
scar ablation	21158
their BBB scores	21185
the final 16 weeks of observation	21217
the final 16 weeks	21217
observation	21239
9.30 ± 0.40 to 9.30 ± 0.37 , n = 10	21252
9.30 ± 0.40	21252
9.30	21252
0.40	21257
9.30 ± 0.37 , n = 10	21265
9.30 ± 0.37	21265
n = 10	21277
n	21277
10	21279
BBB scores from animals with scar ablation but not transplantation	21284
BBB scores	21284
animals with scar ablation but not transplantation	21300
animals with scar ablation	21300
animals	21300
scar ablation	21313
transplantation	21335
no change after scar ablation -LRB- 9.22 ± 0.40 to 9.22 ± 0.40 , n = 9 -RRB-	21358
no change after scar ablation	21358
scar	21374
9.22 ± 0.40 to 9.22 ± 0.40 , n = 9	21389
9.22 ± 0.40	21389
9.22	21389
0.40	21394
9.22 ± 0.40 , n = 9	21402
9.22 ± 0.40 , n	21402
9	21415
Animals receiving both scar ablation and LP transplantation	21419
Animals	21419
both scar ablation and LP transplantation	21437
scar ablation	21442
LP transplantation	21460
a change from 9.44 ± 0.33 before transplantation	21492
9.44 ± 0.33 before	21506
9.44 ±	21506
0.33	21511
9.88 ± 0.35	21542
sixteen weeks	21552
transplantation	21572
n = 8	21589
n	21589
= 8	21590
animals receiving scar ablation and LP/OEC transplantation -LRB- n = 11 -RRB-	21601
animals	21601
scar ablation and LP/OEC transplantation -LRB- n = 11 -RRB-	21619
scar ablation and LP/OEC transplantation	21619
n	21661
11	21663
BBB scores changed from 9.27 ± 0.30 before transplantation to 9.45 ± 0.34	21671
BBB scores	21671
9.27 ± 0.30	21695
transplantation	21713
9.45 ± 0.34	21732
There	21743
no noted significant difference when comparing any two groups or any individual group before and after transplantation -LRB- p > 0.05 -RRB-	21753
no	21753
significant difference	21762
any two groups or any individual group	21800
any two groups	21800
any individual group	21818
transplantation -LRB- p > 0.05 -RRB-	21856
transplantation	21856
p > 0.05	21873
p	21873
> 0.05	21874
>	21874
0.05	21875
Discussion The most important finding from this study	21885
Discussion The most important finding	21885
Discussion	21885
The most important finding	21896
this study	21928
the first time	21952
histological repair of damaged cord tissue	21968
histological repair	21968
damaged cord tissue	21991
a combination of treatments	22030
a combination	22030
treatments	22047
scar ablation and LP/OEC transplantation	22063
scar ablation	22063
LP/OEC transplantation	22081
the lesion cavity in chronically contused rat spinal cord	22109
the lesion cavity	22109
chronically contused rat spinal cord	22130
This tissue repair or anatomical recovery	22168
This tissue repair	22168
anatomical recovery	22190
the prominent expansion of endogenous repaired tissue , obvious reduction even disappearance of the lesion cavity , and the integration of repaired tissue with spared tissue	22230
the prominent expansion	22230
endogenous repaired tissue , obvious reduction even disappearance of the lesion cavity , and the integration of repaired tissue with spared tissue	22257
endogenous	22257
tissue , obvious reduction even disappearance of the lesion cavity , and the integration of repaired tissue with spared tissue	22277
tissue	22277
obvious reduction even disappearance of the lesion cavity	22285
obvious reduction	22285
even disappearance of the lesion cavity	22303
even disappearance	22303
the lesion cavity	22325
the integration of repaired tissue with spared tissue	22348
the integration	22348
repaired tissue with spared tissue	22367
repaired tissue	22367
spared tissue	22388
The tissue repair	22403
a beneficial condition	22430
the P0-positive myelination	22457
ablated glial scar	22508
Our findings	22543
removal of an existing glial scar	22573
removal	22573
an existing glial scar	22584
the tissue repair	22624
Endogenous tissue repair	22643
place	22674
contusion injury	22686
the dorsal part of the cord at the injury epicenter -LRB- Beattie et al. , 1997 ; Zhang et al. , 2011 -RRB-	22719
the dorsal part	22719
the cord at the injury epicenter -LRB- Beattie et al. , 1997 ; Zhang et al. , 2011 -RRB-	22738
the cord	22738
the injury epicenter -LRB- Beattie et al. , 1997 ; Zhang et al. , 2011 -RRB-	22750
the injury epicenter	22750
Beattie	22772
et al. , 1997 ; Zhang et al. , 2011	22780
et al.	22780
1997 ; Zhang et al.	22788
1997	22788
Zhang et al.	22794
Zhang	22794
et al.	22800
2011	22808
contusion injury	22840
a great number of reactive fibroblasts	22858
a great number	22858
reactive fibroblasts	22876
the lesion cavity	22904
the dorsal pia mater	22927
the same time	22952
numerous Schwann cells	22967
the injury epicenter	23008
the dorsal roots	23034
This	23052
the initial , endogenous repaired tissue that contains not only these two cell types , but also novel blood vessels , collagen fibers and regenerating axons myelinated or ensheathed by Schwann cells	23060
the initial , endogenous repaired tissue	23060
not only these two cell types , but also novel blood vessels , collagen fibers and regenerating axons myelinated or ensheathed by Schwann cells	23114
these two cell types	23123
novel blood vessels , collagen fibers and regenerating axons myelinated or ensheathed by Schwann cells	23154
novel blood vessels	23154
collagen fibers	23175
regenerating axons myelinated or ensheathed by Schwann cells	23195
regenerating axons	23195
Schwann cells	23242
The endogenous repaired tissue	23257
three zones : fibrotic , cellular and axonal	23308
three zones	23308
The fibrotic zone	23352
fibroblasts , collagen fibers , and newly formed blood vessels , Schwann cells , regenerating axons	23398
fibroblasts	23398
collagen fibers	23411
newly formed blood vessels	23432
Schwann cells	23460
axons	23488
The cellular zone	23495
densely compacted Schwann cells and some regenerating axons	23528
densely compacted Schwann cells	23528
some regenerating axons	23564
the earlier stage of tissue repair	23592
the earlier stage	23592
tissue repair	23613
the cellular zone	23627
a clear U-shaped shell	23663
the fibrotic zone	23698
it	23721
size	23755
time or following intervention treatments	23765
time	23765
following intervention treatments	23773
The axonal zone	23808
regenerating axons and P0-positive myelin sheaths -LRB- Zhang et al. , 2011 -RRB-	23843
regenerating axons	23843
P0-positive myelin sheaths -LRB- Zhang et al. , 2011 -RRB-	23866
P0-positive myelin sheaths	23866
Zhang	23894
et al. , 2011	23900
et al.	23900
2011	23908
Histological evaluation and quantitative data of repaired tissue in the present study	23915
Histological evaluation and quantitative data	23915
repaired tissue in the present study	23964
repaired tissue	23964
the present study	23983
intervention treatment	24031
endogenous , spontaneous repair processes	24055
spinal cord injury -LRB- Beattie et al. , 1997 ; Belegu et al. , 2007 ; Brook et al. , 2000 ; Inoue et al. , 1998 ; von Euler et al. , 2002 -RRB- , however the repaired tissue was significantly enhanced after scar ablation and LP/OEC transplantation	24130
spinal cord injury -LRB- Beattie et al. , 1997 ; Belegu et al. , 2007 ; Brook et al. , 2000 ; Inoue et al. , 1998 ; von Euler et al. , 2002 -RRB-	24130
spinal cord injury	24130
Beattie et al. , 1997 ; Belegu et al. , 2007 ; Brook et al. , 2000 ; Inoue et al. , 1998 ; von Euler et al. , 2002	24150
Beattie	24150
et al. , 1997 ; Belegu et al. , 2007 ; Brook et al. , 2000 ; Inoue et al. , 1998 ; von Euler et al. , 2002	24158
et al. , 1997	24158
et al.	24158
1997	24166
Belegu et al. , 2007	24172
Belegu	24172
et al. , 2007	24179
et al.	24179
2007	24187
Brook et al. , 2000	24193
Brook	24193
et al. , 2000	24199
et al.	24199
2000	24207
Inoue et al. , 1998	24213
Inoue	24213
et al. , 1998	24219
et al.	24219
1998	24227
von Euler et al. , 2002	24233
von Euler	24233
et al. , 2002	24243
et al.	24243
2002	24251
the repaired tissue	24266
scar ablation and LP/OEC transplantation	24319
scar ablation	24319
LP/OEC transplantation	24337
more and more studies	24371
the OECs	24410
nerve growth factors	24433
the host Schwann cells	24465
the injury site	24502
the tissue	24540
Au et al. , 2007 ; Boyd et al. , 2005 ; Cao et al. , 2007 ; Ramer et al. , 2004	24562
Au	24562
et al. , 2007 ; Boyd et al. , 2005 ; Cao et al. , 2007 ; Ramer et al. , 2004	24565
et al. , 2007	24565
et al.	24565
2007	24573
Boyd et al. , 2005	24579
Boyd	24579
et al. , 2005	24584
et al.	24584
2005	24592
Cao et al. , 2007	24598
Cao	24598
et al. , 2007	24602
et al.	24602
2007	24610
Ramer et al. , 2004	24616
Ramer	24616
et al. , 2004	24622
et al.	24622
2004	24630
OECs	24637
Schwann cell-mediated anatomical and functional repair	24659
NPS injury in adult rats -LRB- You et al. , 2010 -RRB-	24720
NPS injury	24720
adult rats -LRB- You et al. , 2010 -RRB-	24734
adult rats	24734
You	24746
et al. , 2010	24750
et al.	24750
2010	24758
Our observation in the present study	24765
Our observation	24765
the present study	24784
the elements which construct the endogenous repaired tissue at the early stage	24814
the elements	24814
the endogenous repaired tissue at the early stage	24843
the endogenous	24843
tissue	24867
the early stage	24877
the end of the experiment -LRB- 22 weeks after injury -RRB-	24921
the end	24921
the experiment -LRB- 22 weeks after injury -RRB-	24932
the experiment	24932
22 weeks after injury	24948
22 weeks	24948
injury	24963
the repaired tissue	24981
space of the lesion cavity	25028
space	25028
the lesion cavity	25037
combination treatments	25061
the transplanted OECs	25101
more Schwann cells	25163
the injury site	25219
the tissue repair	25267
one of the characteristic features of tissue repair	25300
one	25300
the characteristic features of tissue repair	25307
the characteristic features	25307
tissue repair	25338
the integration of repaired tissue with the spared tissue -LRB- Zhang et al. , 2011 -RRB-	25355
the integration	25355
repaired tissue with the spared tissue -LRB- Zhang et al. , 2011 -RRB-	25374
repaired tissue	25374
the spared tissue -LRB- Zhang et al. , 2011 -RRB-	25395
the spared tissue	25395
Zhang	25414
et al. , 2011	25420
et al.	25420
2011	25428
intervention treatment	25452
spontaneous repair processes	25476
a number of factors including glial scarring -LRB- Webber et al. , 2007 -RRB-	25523
a number	25523
factors including glial scarring -LRB- Webber et al. , 2007 -RRB-	25535
factors	25535
glial scarring -LRB- Webber et al. , 2007 -RRB-	25553
glial scarring	25553
Webber	25569
et al. , 2007	25576
et al.	25576
2007	25584
Data from the present study	25591
Data	25591
the present study	25601
scar ablation	25639
tissue promoted by the LP/OEC transplantation	25672
tissue	25672
the LP/OEC transplantation	25691
the spared tissue , leaving obvious space between repaired tissue	25747
the spared tissue	25747
obvious space between repaired tissue	25774
obvious space	25774
repaired tissue	25796
tissue	25823
the presence of glial scar	25837
the presence	25837
glial scar	25853
the tissue integration	25880
It	25904
a scar ablation	25938
human fetal spinal cord transplants into chronic contusion lesions of rat spinal cord	25954
human fetal spinal cord transplants	25954
chronic contusion lesions of rat spinal cord	25995
chronic contusion lesions	25995
rat spinal cord	26024
welldefined tissue masses that were easily distinguished from the surrounding host tissue	26054
welldefined tissue masses	26054
the surrounding host tissue	26116
heavy GFAP immunoreactivity and a modest degree of host -- graft integration two months	26149
heavy GFAP immunoreactivity	26149
a modest degree of host -- graft integration two months	26181
a modest degree of host	26181
a modest degree	26181
host	26200
graft integration two months	26205
graft integration	26205
two months	26223
transplantation -LRB- Giovanini et al. , 1997 -RRB-	26240
transplantation	26240
Giovanini	26257
et al. , 1997	26267
et al.	26267
1997	26275
Our present observations	26282
those reported results	26327
reliable evidence	26362
prior removal of an existing glial scar	26385
prior removal	26385
an existing glial scar	26402
tissue repair	26442
cell or tissue transplantation -LRB- Geller and Fawcett , 2002 -RRB-	26459
cell or tissue transplantation	26459
Geller and Fawcett	26491
2002	26511
glial scar	26543
two weeks	26560
contusion injury	26576
gliosis	26642
the typical glial scar with a smooth , free surface facing the lesion cavity ,	26651
the typical glial scar	26651
a smooth , free surface facing the lesion cavity	26679
a smooth , free surface	26679
the lesion cavity	26709
2 or 3 layers of reactive astrocytes lining the inner edge of the spared tissue and walls off the lesion cavity to prevent further damage of the cord tissue -LRB- Barrett et al. , 1981 ; Reier et al. , 1989 ; Zhang et al. , 2005 ; Zhang et al. , 2007 -RRB-	26740
2 or 3 layers	26740
reactive astrocytes lining the inner edge of the spared tissue and walls off the lesion cavity to prevent further damage of the cord tissue	26757
reactive astrocytes	26757
the inner edge of the spared tissue and walls	26784
the inner edge	26784
the spared tissue and walls	26802
the spared tissue	26802
walls	26824
the lesion cavity	26834
further damage of the cord tissue	26863
further damage	26863
the cord tissue	26881
Barrett et al. , 1981 ; Reier et al. , 1989 ; Zhang et al. , 2005 ; Zhang et al. , 2007	26898
Barrett	26898
et al. , 1981 ; Reier et al. , 1989 ; Zhang et al. , 2005 ; Zhang et al. , 2007	26906
et al. , 1981	26906
et al.	26906
1981	26914
Reier et al. , 1989	26920
Reier	26920
et al. , 1989	26926
et al.	26926
1989	26934
Zhang et al. , 2005	26940
Zhang	26940
et al. , 2005	26946
et al.	26946
2005	26954
Zhang et al. , 2007	26960
Zhang	26960
et al. , 2007	26966
et al.	26966
2007	26974
levels of CSPGs	26999
levels	26999
CSPGs	27009
time	27035
the physical structure of glial scar tissue , as determined by GFAP immunoreactivity ,	27041
the physical structure	27041
glial scar tissue	27067
GFAP immunoreactivity	27103
much difference -LRB- Camand et al. , 2004 -RRB-	27139
much difference	27139
Camand	27156
et al. , 2004	27163
et al.	27163
2004	27171
Our observations	27178
22 weeks	27209
SCI	27224
the glial scar and lesion cavity	27228
the injury site	27282
prominent modification	27306
that seen 6 weeks after injury	27348
that	27348
6 weeks	27358
injury	27372
LP and/or OEC transplantation after scar ablation	27394
LP	27394
OEC transplantation after scar ablation	27404
OEC transplantation	27404
scar ablation	27430
numerous cells including Schwann cells	27445
numerous cells	27445
Schwann cells	27470
the repaired tissue toward and fill the lesion cavity	27497
the repaired tissue	27497
the lesion cavity	27533
the integration of repaired tissue with the spared tissue	27565
the integration	27565
repaired tissue with the spared tissue	27584
repaired tissue	27584
the spared tissue	27605
almost no space for the reformation of ablated glial scar -LRB- Fig. 4D and E -RRB-	27636
almost no space	27636
the reformation of ablated glial scar -LRB- Fig. 4D and E -RRB-	27656
the reformation	27656
ablated glial scar -LRB- Fig. 4D and E -RRB-	27675
ablated glial scar	27675
Fig. 4D and E	27695
Fig. 4D	27695
E	27707
there	27723
no integration of repaired tissue	27732
no integration	27732
repaired tissue	27750
tissue	27777
the scar reformation	27785
Fig. 4C	27823
The number of P0-positive myelin sheaths in the rats with combination treatments	27833
The number	27833
P0-positive myelin sheaths in the rats with combination treatments	27847
P0-positive myelin sheaths	27847
the rats with combination treatments	27877
the rats	27877
combination treatments	27891
that in the injury	27943
that	27943
the injury	27951
rats	27975
the combination treatments	27997
the P0-positive myelination	28036
many studies	28075
evidence	28099
Schwann cells but not OECs	28113
Schwann cells	28113
Schwann	28113
cells	28121
OECs	28135
the regenerating axons -LRB- OECs may ensheathe the axons -- unmyelinated fibers -RRB- -LRB- Boyd et al. , 2004 ; Boyd et al. , 2005 ; Ramer et al. , 2004 ; Takami et al. , 2002 -RRB-	28150
the regenerating axons -LRB- OECs may ensheathe the axons -- unmyelinated fibers -RRB-	28150
the regenerating axons	28150
OECs	28174
the axons -- unmyelinated fibers	28193
the axons	28193
unmyelinated fibers	28203
Boyd et al. , 2004 ; Boyd et al. , 2005 ; Ramer et al. , 2004 ; Takami et al. , 2002	28224
Boyd	28224
et al. , 2004 ; Boyd et al. , 2005 ; Ramer et al. , 2004 ; Takami et al. , 2002	28229
et al. , 2004	28229
et al.	28229
2004	28237
Boyd et al. , 2005	28243
Boyd	28243
et al. , 2005	28248
et al.	28248
2005	28256
Ramer et al. , 2004	28262
Ramer	28262
et al. , 2004	28268
et al.	28268
2004	28276
Takami et al. , 2002	28282
Takami	28282
et al. , 2002	28289
et al.	28289
2002	28297
they	28313
the same origin	28328
the neural crest -LRB- Barraud et al. , 2010 -RRB-	28349
the neural crest	28349
Barraud	28367
et al. , 2010	28375
et al.	28375
2010	28383
Our previous study	28390
the regenerating axons	28422
Schwann cells	28464
almost 9 times more unmyelinated axons , observed under the electron microscope in a hemisection model of rat	28483
almost 9 times more unmyelinated axons	28483
the electron microscope in a hemisection model of rat	28538
the electron microscope	28538
a hemisection model of rat	28565
a hemisection model	28565
rat	28588
the number of myelinated axons	28593
the number	28593
myelinated axons	28607
the axonal regeneration -LRB- Xu et al. , 1999 -RRB-	28649
the axonal regeneration	28649
Xu	28674
et al. , 1999	28677
et al.	28677
1999	28685
The myelin sheaths formed by Schwann cells at the injury site	28692
The myelin sheaths	28692
Schwann cells	28721
the injury site	28738
monoclonal antibody P0 -LRB- Allen et al. , 2005 ; Yoshimura et al. , 1996 -RRB-	28778
monoclonal antibody P0	28778
Allen	28802
et al. , 2005 ; Yoshimura et al. , 1996	28808
et al.	28808
2005 ; Yoshimura et al.	28816
2005	28816
Yoshimura et al.	28822
Yoshimura	28822
et al.	28832
1996	28840
it	28860
all the axons including the regenerating -LRB- myelinated and unmyelinated -RRB- ones at the injury site by either light or electron microscopy	28880
all the axons	28880
the regenerating -LRB- myelinated and unmyelinated -RRB- ones at the injury site by either light or electron microscopy	28904
the regenerating -LRB- myelinated and unmyelinated -RRB- ones	28904
myelinated and unmyelinated	28922
the injury site	28959
light or electron microscopy	28985
it	29026
the number of P0-positive myelin sheaths obtained from the epicenter as an indicator to evaluate the trend of axonal regeneration	29050
the number	29050
P0-positive myelin sheaths obtained from the epicenter as an indicator to evaluate the trend of axonal regeneration	29064
P0-positive myelin sheaths	29064
the epicenter as an indicator	29105
the epicenter	29105
an indicator	29122
the trend of axonal regeneration	29147
the trend	29147
axonal regeneration	29160
The increase in number of P0 - positive myelin sheaths	29181
The increase	29181
number of P0 - positive myelin sheaths	29197
number of P0	29197
number	29197
P0	29207
myelin sheaths	29220
the effect of endogenous Schwann cells stimulated by transplanted OECs -LRB- Eftekharpour et al. , 2008 ; Pearse et al. , 2007 -RRB-	29251
the effect	29251
endogenous Schwann cells stimulated by transplanted OECs -LRB- Eftekharpour et al. , 2008 ; Pearse et al. , 2007 -RRB-	29265
endogenous Schwann cells	29265
transplanted OECs -LRB- Eftekharpour et al. , 2008 ; Pearse et al. , 2007 -RRB-	29304
transplanted OECs	29304
Eftekharpour	29323
et al. , 2008 ; Pearse et al. , 2007	29336
et al.	29336
2008 ; Pearse et al.	29344
2008	29344
Pearse et al.	29350
Pearse	29350
et al.	29357
2007	29365
these observations	29381
we	29401
the combination treatments including scar ablation and transplantation of LP/OEC	29417
the combination treatments	29417
scar ablation and transplantation of LP/OEC	29454
scar ablation and transplantation	29454
LP/OEC	29491
not only the tissue repair , but also the P0-positive myelination , which may imply the axonal regeneration	29506
the tissue repair	29515
the P0-positive myelination , which may imply the axonal regeneration	29543
the P0-positive myelination	29543
the axonal regeneration	29588
this study , remarkable tissue repair and increase of P0	29616
this study	29616
remarkable tissue repair	29628
increase of P0	29657
increase	29657
P0	29669
positive myelination	29673
significant locomotor recovery	29712
The reasons	29744
poor neural plasticity	29799
the injury	29828
One possibility	29840
those regenerating axons	29864
the target location	29906
effective synaptic connection	29939
Another possibility	29970
most of these regenerating axons	29998
most	29998
these regenerating axons	30006
abnormal or non-existent impulse conduction	30036
SCI locomotor	30087
recovery	30101
an effective number of regenerating axons , reestablishment of synaptic connections , restoration of nerve conduction and the remaining ability of muscle movement -LRB- Carlson , 1989 ; Collazos-Castro et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989 -RRB-	30126
an effective number of regenerating axons	30126
an effective number	30126
regenerating axons	30149
reestablishment of synaptic connections	30169
reestablishment	30169
synaptic connections	30188
restoration of nerve conduction	30210
restoration	30210
nerve conduction	30225
the remaining ability of muscle movement -LRB- Carlson , 1989 ; Collazos-Castro et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989 -RRB-	30246
the remaining ability	30246
muscle movement -LRB- Carlson , 1989 ; Collazos-Castro et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989 -RRB-	30271
muscle movement	30271
Carlson , 1989 ; Collazos-Castro et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989	30288
Carlson	30288
1989 ; Collazos-Castro et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989	30297
1989	30297
Collazos-Castro et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989	30303
Collazos-Castro	30303
et al. , 2006 ; Fawcett , 2002 ; Fry , 2001 ; Schwab , 2002 ; Young , 1989	30319
et al. , 2006	30319
et al.	30319
2006	30327
Fawcett , 2002	30333
Fawcett	30333
2002	30342
Fry , 2001	30348
Fry	30348
2001	30353
Schwab , 2002	30359
Schwab	30359
2002	30367
Young , 1989	30373
Young	30373
1989	30380
the present study	30390
we	30408
a number of P0-positive myelination	30420
a number	30420
P0-positive myelination	30432
the injury epicenter	30459
we	30485
these axons	30503
functional locations	30528
new synaptic connections	30567
All this	30593
additional therapies , such as the administration of physical therapy	30616
additional therapies	30616
the administration of physical therapy	30646
the administration	30646
physical therapy	30668
the elongation of regenerating axons	30715
the elongation	30715
regenerating axons	30733
effective synaptic connections	30798
the formation of activitydependent plasticity	30848
the formation	30848
activitydependent plasticity	30865
both sensory and motor function -LRB- Barnett and Chang , 2004 ; Barnett and Riddell , 2007 -RRB-	30905
both sensory	30905
motor function -LRB- Barnett and Chang , 2004 ; Barnett and Riddell , 2007 -RRB-	30922
motor function	30922
Barnett and Chang , 2004 ; Barnett and Riddell , 2007	30938
Barnett and Chang	30938
2004 ; Barnett and Riddell	30957
2004	30957
Barnett and Riddell	30963
2007	30984
conclusion	30994
the data from this study	31006
the data	31006
this study	31020
chronically contused rat spinal cord	31047
spontaneous repair processes	31085
tissue	31147
combination treatments	31187
scar ablation and LP/OEC transplantation	31215
scar ablation	31215
LP/OEC transplantation	31233
Tissue repair characterized by profound expansion of endogenous repaired tissue , remarkable reduction or disappearance of the lesion cavity , and integration of repaired tissue with spared tissue	31257
Tissue repair	31257
profound expansion of endogenous repaired tissue , remarkable reduction or disappearance of the lesion cavity , and integration of repaired tissue with spared tissue	31288
profound expansion	31288
endogenous repaired tissue , remarkable reduction or disappearance of the lesion cavity , and integration of repaired tissue with spared tissue	31310
endogenous	31310
tissue , remarkable reduction or disappearance of the lesion cavity , and integration of repaired tissue with spared tissue	31330
tissue	31330
remarkable reduction or disappearance of the lesion cavity	31338
remarkable reduction or disappearance	31338
the lesion cavity	31379
integration of repaired tissue with spared tissue	31402
integration	31402
repaired tissue with spared tissue	31417
repaired tissue	31417
spared tissue	31438
a beneficial environment for axonal regeneration and prevention of scar reformation	31464
a beneficial environment	31464
axonal regeneration and prevention	31493
scar reformation	31531
The findings in this study	31549
The findings	31549
this study	31565
removal of an existing glial scar	31598
removal	31598
an existing glial scar	31609
the tissue repair	31649
the combination treatments	31677
significant locomotion improvement	31722
these findings	31758
further study	31811
the functional recovery promoted by the functional electrical stimulation-based physical therapy	31836
the functional recovery	31836
the functional electrical stimulation-based physical therapy	31872
Experimental procedures 4.1 .	31938
Experimental procedures	31938
4.1	31962
Animal Adult female Long -- Evans rats weighing 200 -- 220 g	31967
Animal Adult female Long	31967
Animal Adult	31967
Evans rats	31992
200	32012
220 g	32016
the present study	32036
They	32055
plastic cages on 12 h light/dark cycles	32082
plastic cages	32082
12 h light/dark cycles	32099
free moving space and free access to drinking water and standard food	32127
free moving space	32127
free access to drinking water and standard food	32149
free access	32149
drinking water and standard food	32164
drinking water	32164
standard food	32183
All rats	32198
contusion injury	32216
several groups -LRB- Table 1 -RRB-	32264
several groups	32264
Table 1	32280
The control animals	32290
contusion injury only -LRB- SCI Control , i.e. , SCI 22w , n = 10 -RRB-	32319
contusion injury only	32319
contusion injury	32319
SCI Control , i.e.	32342
SCI Control	32342
i.e.	32355
SCI 22w , n = 10	32361
SCI 22w	32361
n = 10	32370
n	32370
10	32372
the rest	32380
scar ablation/transplantation	32398
6 weeks	32428
SCI	32442
Animals in two groups	32447
Animals	32447
two groups	32458
LP -LRB- SCI+LP , n = 11 -RRB- or LP plus OEC -LRB- SCI+LP+OEC , n = 10 -RRB- transplantation	32478
LP -LRB- SCI+LP , n = 11 -RRB- or LP	32478
LP -LRB- SCI+LP , n = 11 -RRB-	32478
LP	32478
SCI+LP , n = 11	32482
SCI+LP	32482
n = 11	32490
n	32490
11	32492
LP	32499
OEC -LRB- SCI+LP+OEC , n = 10 -RRB- transplantation	32507
OEC	32507
SCI+LP+OEC , n = 10	32512
SCI+LP+OEC	32512
n = 10	32524
n	32524
10	32526
transplantation	32530
scar ablation	32554
Animals in the other three groups	32569
Animals	32569
the other three groups	32580
scar ablation -LRB- SCI+SA , n = 12 -RRB- or scar ablation followed by LP -LRB- SCI+SA+LP , n = 8 -RRB- or LP plus OEC -LRB- SCI+SA+LP+OEC , n = 11 -RRB- transplantation	32612
scar ablation -LRB- SCI+SA , n = 12 -RRB-	32612
scar ablation	32612
SCI+SA , n = 12	32627
SCI+SA	32627
n = 12	32635
n	32635
12	32637
scar ablation followed by LP -LRB- SCI+SA+LP , n = 8 -RRB- or LP plus OEC -LRB- SCI+SA+LP+OEC , n = 11 -RRB- transplantation	32644
scar ablation	32644
LP -LRB- SCI+SA+LP , n = 8 -RRB- or LP plus OEC -LRB- SCI+SA+LP+OEC , n = 11 -RRB- transplantation	32670
LP -LRB- SCI+SA+LP , n = 8 -RRB-	32670
LP	32670
SCI+SA+LP , n = 8	32674
SCI+SA+LP	32674
n = 8	32685
n	32685
8	32687
LP plus OEC -LRB- SCI+SA+LP+OEC , n = 11 -RRB- transplantation	32693
LP	32693
OEC -LRB- SCI+SA+LP+OEC , n = 11 -RRB- transplantation	32701
OEC	32701
SCI+SA+LP+OEC , n = 11	32706
SCI+SA+LP+OEC	32706
n = 11	32721
n	32721
11	32723
transplantation	32727
deep anesthesia with sodium pentobarbital -LRB- 60 mg/kg , ip -RRB-	32750
deep anesthesia	32750
sodium pentobarbital -LRB- 60 mg/kg , ip -RRB-	32771
sodium pentobarbital	32771
60 mg/kg , ip	32793
60 mg/kg	32793
ip	32803
all animals	32808
phosphatebuffered 4 % paraformaldehyde 22 weeks	32854
phosphatebuffered 4 % paraformaldehyde	32854
22 weeks	32892
contusion injury or 16 weeks	32907
contusion injury	32907
16 weeks	32927
transplantation	32942
addition	32962
5 additional control rats -LRB- SCI 6w -RRB-	32972
5 additional control rats	32972
SCI 6w	32999
6 weeks	33021
contusion injury for the study of glial scar formation and P0 - positive myelin sheath evaluation , and 3 rats	33035
contusion injury	33035
the study of glial scar formation and P0 - positive myelin sheath evaluation , and 3 rats	33056
the study of glial scar formation	33056
the study	33056
glial scar formation	33069
P0	33094
positive myelin sheath evaluation	33098
3 rats	33137
8 weeks	33158
scar ablation	33172
transplantation for the study of glial scar reformation	33194
transplantation	33194
the study of glial scar reformation	33214
the study	33214
glial scar reformation	33227
All spinal cords	33251
histological evaluation	33287
All surgical procedures , including interventions and preand post-surgery care ,	33312
All surgical procedures	33312
interventions and preand post-surgery care	33347
interventions	33347
preand post-surgery care	33365
the Institutional Animal Use and Care Committee of Colorado	33408
the Institutional Animal Use and Care Committee	33408
Colorado	33459
the Guide for the Care and Use of Laboratory Animals -LRB- 1996 -RRB-	33492
the Guide for the Care and Use of Laboratory Animals	33492
the Care	33506
Laboratory	33526
1996	33546
4.2	33553
Characterization of primary antibodies	33558
Characterization	33558
primary antibodies	33578
Table 2 for a list of all primary antibodies used in this study	33613
Table 2	33613
a list of all primary antibodies used in this study	33625
a list	33625
all primary antibodies used in this study	33635
all primary antibodies	33635
this study	33666
The GFAP antibodies	33678
cells	33711
the classic morphology and distribution of glial fibrillary acidic protein	33722
the classic morphology and distribution	33722
glial fibrillary acidic protein	33765
a pattern that is identical to that previously reported -LRB- Moon and Fawcett , 2001 -RRB-	33808
a pattern that is identical to that previously reported	33808
a pattern	33808
that previously reported	33839
that	33839
Moon and Fawcett	33865
2001	33883
The anti-P0 antibody	33890
the IgG or IgM class	33923
the expected myelin sheaths of peripheral nerve in paraffin-embedded sections , but not the myelin sheathes of the normal spinal cord -LRB- Buss et al. , 2007 ; Lee et al. , 1997 -RRB-	33965
the expected myelin sheaths of peripheral nerve in paraffin-embedded sections	33965
the expected myelin sheaths	33965
peripheral nerve	33996
paraffin-embedded sections	34016
the myelin sheathes of the normal spinal cord -LRB- Buss et al. , 2007 ; Lee et al. , 1997 -RRB-	34052
the myelin sheathes	34052
the normal spinal cord -LRB- Buss et al. , 2007 ; Lee et al. , 1997 -RRB-	34075
the normal spinal cord	34075
Buss	34099
et al. , 2007 ; Lee et al. , 1997	34104
et al.	34104
2007 ; Lee et al.	34112
2007	34112
Lee et al.	34118
Lee	34118
et al.	34122
1997	34130
P0-positive myelin sheaths in the repaired tissue	34137
P0-positive myelin sheaths	34137
the repaired tissue	34167
newly formed myelin sheaths which contain an axon	34206
an axon	34248
The α-p75NTR antibody	34257
larger	34290
olfactory ensheathing cells and small spindle-shaped Schwann cells	34305
the culture that was identical with previous description -LRB- Mackay-Sim , 2005 ; Plant et al. , 2002 ; Shyu et al. , 2008 -RRB-	34375
the culture	34375
previous description	34411
Mackay-Sim , 2005 ; Plant et al. , 2002 ; Shyu et al. , 2008	34433
Mackay-Sim	34433
2005 ; Plant et al. , 2002 ; Shyu et al.	34445
2005	34445
Plant et al. , 2002 ; Shyu et al.	34451
Plant	34451
et al. , 2002 ; Shyu et al.	34457
et al. , 2002	34457
et al.	34457
2002	34465
Shyu et al.	34471
Shyu	34471
et al.	34476
2008	34484
Mouse monoclonal antibody against neurofilament , a widely used antibody ,	34491
Mouse monoclonal antibody against neurofilament	34491
Mouse monoclonal antibody	34491
neurofilament	34525
a widely used antibody	34540
all axons	34575
the spinal cord	34588
The basic morphology of stained axons	34605
The basic morphology	34605
axons	34637
previous description -LRB- Schmidt et al. , 1987 ; Trojanowski , 1987 -RRB-	34662
previous description	34662
Schmidt	34684
et al. , 1987 ; Trojanowski , 1987	34692
et al.	34692
1987 ; Trojanowski	34700
1987	34700
Trojanowski	34706
1987	34719
4.3	34726
Preparation of LP and OECs for transplantation 4.3.1 .	34731
Preparation	34731
LP and OECs	34746
transplantation 4.3.1	34762
Preparation of LP The olfactory mucosa , devoid of the respiratory mucosa , was isolated from the nasal septum of a donor animal and was placed in Dispase II -LRB- Roche -RRB- for 35 -- 40 min at 37 °C .	34785
Preparation of LP The olfactory mucosa , devoid of the respiratory mucosa , was isolated from the nasal septum of a donor animal and was placed in Dispase II -LRB- Roche -RRB- for 35	34785
Preparation	34785
LP The olfactory mucosa , devoid of the respiratory mucosa , was isolated from the nasal septum of a donor animal and was placed in Dispase II -LRB- Roche -RRB- for 35	34800
LP	34800
The olfactory mucosa , devoid of the respiratory mucosa ,	34803
The olfactory mucosa	34803
the respiratory mucosa	34835
the nasal septum of a donor animal	34877
the nasal septum	34877
a donor animal	34897
Dispase II -LRB- Roche -RRB- for 35	34930
Dispase II -LRB- Roche -RRB-	34930
Dispase II	34930
Roche	34942
35	34953
40 min at 37 °C	34956
40 min	34956
37 °C	34966
The olfactory epithelium	34973
forceps thereby exposing the LP -LRB- Fig. 1A and B -RRB-	35028
forceps	35028
the LP -LRB- Fig. 1A and B -RRB-	35053
the LP	35053
Fig. 1A and B	35061
Fig. 1A	35061
B	35073
transplant	35081
the LP	35093
2.0 ×	35113
2.0 mm -LRB- LP-Only -RRB- or 1.5 × 1.5 mm -LRB- LP+OEC s -RRB- squares	35117
2.0 mm -LRB- LP-Only -RRB-	35117
LP-Only	35124
1.5 × 1.5 mm -LRB- LP+OEC s -RRB-	35136
1.5 × 1.5 mm	35136
1.5	35136
1.5 mm	35140
LP+OEC s	35147
squares	35156
ice in L-15	35176
ice	35176
L-15	35183
transplant	35194
One piece of LP	35206
One piece	35206
LP	35219
one rat	35235
4.3.2	35244
Preparation of OECs OECs	35251
Preparation	35251
OECs OECs	35266
adult Long	35295
Evans LP following basic protocols	35306
Evans LP	35306
basic protocols	35325
elsewhere -LRB- Au and Roskams , 2002 -RRB-	35350
elsewhere	35350
Au and Roskams	35361
2002	35377
OEC culture	35400
LP isolated as described above	35413
LP	35413
37 °C in collagenase	35460
37 °C	35460
collagenase	35469
30 min followed by incubation in SD -LRB- Soybean Trypsin inhibitor/DNase -RRB- solution for 15 min	35485
30 min	35485
incubation	35504
SD -LRB- Soybean Trypsin inhibitor/DNase -RRB- solution for 15 min	35518
SD -LRB- Soybean Trypsin inhibitor/DNase -RRB- solution	35518
SD -LRB- Soybean Trypsin inhibitor/DNase -RRB-	35518
SD	35518
Soybean Trypsin inhibitor/DNase	35522
15 min	35568
The tissue	35576
3 times	35616
22	35632
25 gauge	35639
growth medium	35661
400 × g	35684
growth	35705
medium on a matrigel-coated T25 flask	35712
medium	35712
a matrigel-coated T25 flask	35722
Twenty-four hours	35751
non-adherent cells	35784
fresh media	35820
the culture	35848
Cultures	35861
an additional 4	35885
7 days until nearly confluent	35901
7 days	35901
contaminating fibroblasts	35947
the OEC cultures -LRB- Noble and Murray , 1984 -RRB-	35978
the OEC cultures	35978
Noble and Murray	35996
1984	36014
cells among which may still contain some Schwann cells -LRB- Rizek and Kawaja , 2006 -RRB-	36021
cells	36021
some Schwann cells -LRB- Rizek and Kawaja , 2006 -RRB-	36057
some Schwann cells	36057
Rizek and Kawaja	36077
2006	36095
liquid nitrogen in working aliquots	36130
liquid nitrogen	36130
working aliquots	36149
4.3.3	36167
Immunostaining of cell cultures	36174
Immunostaining	36174
cell cultures	36192
transplantation , cultures of CD90-negative OECs	36215
transplantation	36215
cultures of CD90-negative OECs	36232
cultures	36232
CD90-negative OECs	36244
matrigel-coated 8-well chamber slides	36278
a density of ~ 3000 cells/cm2	36319
a density	36319
~ 3000 cells/cm2	36332
~	36332
3000 cells/cm2	36333
the following day	36352
cells	36371
1	36389
PBS	36397
4 % paraformaldehyde	36411
4 % goat serum in 0.1 % Triton X-100 / PBS	36479
4 % goat serum	36479
0.1 % Triton X-100 / PBS	36496
0.1 % Triton X-100	36496
PBS	36514
Cellswere	36519
1:100 mouse α-p75NTR -LRB- Abcam , Cambridge , MA #MC -192 -RRB- and 1:500 rabbit α-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- Dako , Glostrup Denmark #Z0334 -RRB-	36557
1:100 mouse α-p75NTR -LRB- Abcam , Cambridge , MA #MC -192 -RRB-	36557
1:100 mouse α-p75NTR	36557
Abcam , Cambridge , MA #MC -192	36578
Abcam	36578
Cambridge , MA #MC -192	36585
1:500 rabbit α-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- Dako , Glostrup Denmark #Z0334 -RRB-	36612
1:500 rabbit	36612
α-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- Dako , Glostrup Denmark #Z0334 -RRB-	36625
α-glial fibrillary acidic protein -LRB- GFAP -RRB-	36625
α-glial fibrillary acidic protein	36625
GFAP	36660
Dako , Glostrup Denmark #Z0334	36667
Dako	36667
Glostrup Denmark #Z0334	36673
1 h	36702
room temperature	36709
Primary antibodies	36727
a 1:1000 dilution goat anti-mouse IgG Alexa-568 and goat anti-rabbit Alexa-488 secondary antibodies -LRB- Molecular Probes , Eugene , OR -RRB-	36765
a 1:1000 dilution goat anti-mouse IgG Alexa-568	36765
a 1:1000 dilution goat	36765
anti-mouse IgG Alexa-568	36788
goat anti-rabbit Alexa-488 secondary antibodies -LRB- Molecular Probes , Eugene , OR -RRB-	36817
goat anti-rabbit Alexa-488	36817
secondary antibodies -LRB- Molecular Probes , Eugene , OR -RRB-	36844
secondary antibodies	36844
Molecular Probes	36866
Eugene	36884
OR	36892
aqua polymount -LRB- Polyscience , Niles , IL -RRB- , cellswere stainedwith 2 μg/ml Hoeschst -LRB- Sigma , St. Louis , MO -RRB- for 5 min	36918
aqua polymount -LRB- Polyscience , Niles , IL -RRB-	36918
aqua polymount	36918
Polyscience	36934
Niles	36947
IL	36954
cellswere stainedwith 2 μg/ml Hoeschst -LRB- Sigma , St. Louis , MO -RRB- for 5 min	36959
cellswere stainedwith	36959
2 μg/ml Hoeschst -LRB- Sigma , St. Louis , MO -RRB- for 5 min	36981
2 μg/ml Hoeschst -LRB- Sigma , St. Louis , MO -RRB-	36981
2 μg/ml Hoeschst	36981
Sigma	36999
St. Louis	37006
MO	37017
5 min	37025
Images	37031
an Olympus IX70 inverted microscope equipped with a FVII camera -LRB- Olympus -RRB- and Microsuite imaging software -LRB- Olympus -RRB- -LRB- Fig. 1C -RRB-	37057
an Olympus IX70 inverted microscope	37057
a FVII camera -LRB- Olympus -RRB- and Microsuite imaging software -LRB- Olympus -RRB- -LRB- Fig. 1C -RRB-	37107
a FVII camera -LRB- Olympus -RRB-	37107
a FVII camera	37107
Olympus	37122
Microsuite imaging software -LRB- Olympus -RRB- -LRB- Fig. 1C -RRB-	37135
Microsuite imaging software -LRB- Olympus -RRB-	37135
Microsuite imaging software	37135
Olympus	37164
Fig. 1C	37174
4.4	37184
Spinal cord injury and postoperative animal care The contusion injury to the rat spinal cord	37189
Spinal cord injury	37189
postoperative animal care The contusion injury to the rat spinal cord	37212
postoperative animal care	37212
The contusion injury to the rat spinal cord	37238
The contusion injury	37238
the rat spinal cord	37262
the NYU -LRB- New York University -RRB- impactor device as described before -LRB- Zhang et al. , 2000 -RRB-	37303
the NYU -LRB- New York University -RRB- impactor device as described before	37303
the NYU -LRB- New York University -RRB- impactor device	37303
New York University	37312
Zhang	37370
et al. , 2000	37376
et al.	37376
2000	37384
deep anesthesia with sodium pentobarbital -LRB- 50 mg/kg , ip -RRB-	37406
deep anesthesia	37406
sodium pentobarbital -LRB- 50 mg/kg , ip -RRB-	37427
sodium pentobarbital	37427
50 mg/kg , ip	37449
50 mg/kg	37449
ip	37459
the vertebral column	37464
the spinous process	37517
vertebra	37540
thoracic -LRB- T -RRB- level T7 and T10	37549
thoracic -LRB- T -RRB-	37549
level T7 and T10	37562
a dorsal laminectomy	37580
the spinal cord	37619
the dura intact	37652
the dura	37652
the 10 g impact rod	37674
spinal cord segment T10	37709
a height of 25 mm	37738
a height	37738
25 mm	37750
it	37761
hind limb	37776
locomotor deficits as described previously -LRB- Constantini and Young , 1994 -RRB-	37786
locomotor deficits as described previously	37786
locomotor deficits	37786
Constantini and Young	37830
1994	37853
pain	37871
analgesia buprenorphine -LRB- 0.02 mg/kg , sc -RRB-	37877
analgesia buprenorphine	37877
0.02 mg/kg , sc	37902
0.02 mg/kg	37902
sc	37914
the first 2 days	37947
injury/surgery	37970
The antibiotic cephazolin -LRB- 20 mg/kg , sc -RRB-	37986
The antibiotic cephazolin	37986
20 mg/kg , sc	38013
20 mg/kg	38013
sc	38023
twice a day	38040
one week	38056
Urinary bladders	38066
hand	38109
twice a day	38114
adequate spontaneous voiding returned	38132
adequate spontaneous voiding	38132
attention	38174
the body	38201
addition	38218
saline solution -LRB- 0.9 % , 10 ml , sc -RRB-	38228
saline solution	38228
0.9 %	38245
10 ml	38251
sc	38258
one	38289
week	38293
dehydration	38309
The animals	38322
the first two weeks	38360
surgery and once a week	38386
surgery	38386
once a week	38398
Animals	38421
5 -- 10 % of their body weight	38442
5	38442
10 % of their body weight	38444
10 %	38444
their body weight	38451
the first week	38476
injury	38497
the loss of body weight	38508
the loss	38508
body weight	38520
more than 15 %	38536
more saline solution	38551
more saline	38551
solution	38563
4.5	38583
Photochemical scar ablation Six weeks after contusion injury photochemical scar ablation	38588
Photochemical scar ablation	38588
Six weeks	38616
contusion injury photochemical scar ablation	38632
contusion injury	38632
the injury epicenter of the spinal cord as previously described -LRB- Zhang et al. , 2007 -RRB-	38694
the injury epicenter	38694
the spinal cord as previously described -LRB- Zhang et al. , 2007 -RRB-	38718
the spinal cord	38718
Zhang	38759
et al. , 2007	38765
et al.	38765
2007	38773
deep anesthesia with sodium pentobarbital	38795
deep anesthesia	38795
sodium pentobarbital	38816
the wound	38838
the injury site of the spinal cord	38865
the injury site	38865
the spinal cord	38884
dura intact	38917
dura	38917
One -LRB- 1.0 -RRB- microliter of 2 %	38930
One -LRB- 1.0 -RRB- microliter	38930
One -LRB- 1.0 -RRB-	38930
One	38930
1.0	38935
2 %	38954
Bengal in saline	38962
Bengal	38962
saline	38972
the course of 1 min	39013
the course	39013
1 min	39027
the lesion cavity	39038
a narrow bore -LRB- ~ 100 μm -RRB- , glass pipette connected to a Digital Microdispenser -LRB- Drummond Scientific Co. , Broomall , PA , USA -RRB-	39064
a narrow bore -LRB- ~ 100 μm -RRB-	39064
a narrow bore	39064
a narrow	39064
~ 100 μm	39079
glass pipette connected to a Digital Microdispenser -LRB- Drummond Scientific Co. , Broomall , PA , USA -RRB-	39089
glass pipette connected to a Digital Microdispenser	39089
glass pipette	39089
a Digital Microdispenser	39116
Drummond Scientific Co. , Broomall , PA , USA	39142
Drummond Scientific Co.	39142
Broomall	39167
PA	39177
USA	39181
The	39187
Bengal within the cavity	39196
Bengal	39196
the cavity	39210
8 min	39248
injection	39260
the cytoplasm of the superficial astrocytes of the glial scar tissue	39299
the cytoplasm	39299
the superficial astrocytes of the glial scar tissue	39316
the superficial astrocytes	39316
the glial scar tissue	39346
the injury site	39369
5 min	39405
the full spectrum light of a halogen bulb -LRB- 150 W , 7 cm distance -RRB-	39415
the full spectrum light	39415
a halogen bulb -LRB- 150 W , 7 cm distance -RRB-	39442
a halogen bulb	39442
150 W	39458
7 cm distance	39465
damage	39492
the cord tissue	39502
the heating source from the halogen light	39521
the heating source	39521
the halogen light	39545
the exposed part of spinal cord	39564
the exposed part	39564
spinal cord	39584
room temperature saline solution	39612
fresh change each 30 -- 40 s during the illuminating time	39650
fresh change each 30	39650
fresh change each	39650
fresh change	39650
each	39663
30	39668
40 s during the illuminating time	39671
40 s	39671
the illuminating time	39683
the absorption of rose Bengal by glial scar cells	39717
the absorption	39717
Bengal	39740
glial scar cells	39750
two rats	39768
phosphatebuffered 4 % paraformaldehyde 8 min after rose Bengal injection into the lesion cavity without light illumination	39811
phosphatebuffered 4 % paraformaldehyde 8 min	39811
Bengal injection	39866
the lesion cavity	39888
light illumination	39914
the spinal cords	39934
cryosection	39970
Sections without any staining	39983
Sections	39983
any staining	40000
the light microscope	40033
the location of rose Bengal within the lesion cavity -LRB- Fig. 2C -RRB-	40066
the location	40066
Bengal	40087
the lesion cavity -LRB- Fig. 2C -RRB-	40101
the lesion cavity	40101
Fig. 2C	40120
4.6	40130
Implantation of LP or OECs Implantation	40135
Implantation	40135
LP or OECs Implantation	40151
LP	40151
OECs Implantation	40157
the injury site	40206
photochemical scar ablation	40243
the surgical microscope	40278
the dura	40302
a 1 mm long opening of the lesion cavity	40342
a 1 mm long opening	40342
1 mm	40344
the lesion cavity	40365
a sharp blade on the median line of spinal cord	40397
a sharp blade	40397
the median line of spinal cord	40414
the median line	40414
spinal cord	40433
the injury epicenter	40448
One piece of the soft LP	40470
One piece	40470
the soft LP	40483
the cavity with the help of forceps	40524
the cavity	40524
the help of forceps	40540
the help	40540
forceps	40552
two groups	40564
1 or 2 μl of OECs	40576
1 or 2 μl	40576
OECs	40589
6 × 106	40595
6 ×	40595
106	40597
suspension	40602
the opening cavity	40631
a 31 gauge metal needle connected to a Hamilton syringe prior LP delivery	40658
a 31 gauge metal needle	40658
a Hamilton syringe	40695
LP delivery	40720
the dura	40744
a 10	40781
0 Novafil nylon suture -LRB- Ethicon , Somerville , NJ , USA -RRB-	40786
0 Novafil nylon suture	40786
Ethicon	40810
Somerville	40819
NJ , USA	40831
the invasion of connective tissue scar	40850
the invasion	40850
connective tissue scar	40866
The muscle and skin	40890
proper sutures	40927
glial scar	40959
the transplanted LP	40985
the lesion cavity	41023
two rats	41042
2 h	41065
scar ablation and LP transplantation	41075
scar ablation	41075
LP transplantation	41093
the spinal cords	41117
histological observation	41153
others -LRB- Fig. 2D -RRB-	41181
others	41181
Fig. 2D	41189
the survival of transplanted LP	41233
the survival	41233
transplanted LP	41249
we	41265
GFP-positive LP	41281
the lesion cavity	41302
the same procedures asmentioned above	41325
the same procedures	41325
the tissues	41372
a GFP-positive strain of Sprague -- Dawley rats	41402
a GFP-positive strain of Sprague	41402
a GFP-positive strain	41402
Sprague	41427
Dawley rats	41435
the same strain of rats rather than our standard model rat Long -- Evans	41448
the same strain	41448
rats rather than our standard model rat Long -- Evans	41467
rats rather than our standard model rat Long	41467
rats	41467
our standard model rat	41484
Evans	41512
the transplantation	41532
potential cross-species	41561
tissue rejection	41585
The LP donor SD-Tg	41603
GFP	41623
2BalRrrc rats	41628
SD stock	41654
EGFP transgene	41672
ubiquitin C promoter and ubiquitous GFP expression	41692
ubiquitin C promoter	41692
ubiquitous GFP expression	41717
These rats with GFP-LP transplantation -LRB- n = 3 -RRB-	41744
These rats with GFP-LP transplantation	41744
These rats	41744
GFP-LP transplantation	41760
n	41784
3	41786
8 weeks	41803
analysis	41851
the fluorescent microscope	41866
Antibodies GFAP against astrocytes , and NF Ab-7 against neurofilaments	41894
Antibodies GFAP	41894
astrocytes , and NF Ab-7 against neurofilaments	41918
astrocytes	41918
NF Ab-7 against neurofilaments	41934
NF Ab-7	41934
neurofilaments	41950
these targets	41988
these animals	42006
4.7	42021
Histology and immunohistochemistry	42026
Histology	42026
immunohistochemistry	42040
perfusion	42079
the spinal cords	42090
the identical fixative overnight	42133
Ten mm-long cord	42167
the injury site	42203
alcohols , cleared in xylene	42250
alcohols	42250
xylene	42271
paraffin wax	42294
The cross	42308
paraffin sections -LRB- 10 μm thick -RRB- were cut at the injury epicenter and stained routinely -LRB- hematoxylin and eosin , H.E. -RRB- and/or immunohistochemically	42318
paraffin sections -LRB- 10 μm thick -RRB- were cut at the injury epicenter and stained routinely -LRB- hematoxylin and eosin , H.E. -RRB- and/or	42318
paraffin sections	42318
10 μm	42337
the injury epicenter	42362
hematoxylin and eosin , H.E.	42406
hematoxylin and eosin	42406
H.E.	42429
and/or	42435
immunostaining	42469
the sections	42485
xylene	42521
a series of ethanol and distilled water	42546
a series	42546
ethanol and distilled water	42558
Sections	42587
the Antigen Retrieval Citra solution -LRB- BioGenex , San Ramon , CA -RRB- for 15 min	42611
the Antigen Retrieval Citra solution -LRB- BioGenex , San Ramon , CA -RRB-	42611
the Antigen Retrieval Citra solution	42611
BioGenex	42649
San Ramon	42659
CA	42670
15 min	42678
the endogenous peroxidase	42696
the sections	42722
3 % H2O2 in 50 mM Tris-buffered saline containing 0.1 % Triton X-100 -LRB- TTBS -RRB- pH 7.5 , for 30 min at room temperature -LRB- RT -RRB-	42755
3 % H2O2	42755
50 mM Tris-buffered saline	42766
0.1 % Triton X-100 -LRB- TTBS -RRB- pH 7.5	42804
0.1 % Triton X-100 -LRB- TTBS -RRB-	42804
0.1 % Triton X-100	42804
TTBS	42823
30 min at room temperature	42841
30 min	42841
room temperature	42851
RT	42869
The normal goat serum -LRB- 2 % in TTBS -RRB-	42874
The normal goat serum	42874
2 % in TTBS	42897
2 %	42897
TTBS	42903
60 min	42920
RT	42930
the tissue to block non-specific antigens	42937
non-specific antigens	42957
primary antibodies diluted in TTBS with 1 % normal goat serum in a humidified chamber overnight at RT	43001
primary antibodies	43001
TTBS with 1 % normal goat serum	43031
TTBS	43031
1 % normal goat serum	43041
a humidified chamber overnight	43065
RT	43099
the sections	43103
1:200 biotinylated goat anti-mouse IgG -LRB- Jackson -RRB- for 60 min and then in 1:500 streptavidin peroxidase -LRB- Jackson -RRB- for 60 min in the same buffer	43145
1:200	43145
goat anti-mouse IgG -LRB- Jackson -RRB- for 60 min and then	43164
goat anti-mouse IgG -LRB- Jackson -RRB-	43164
goat anti-mouse IgG	43164
Jackson	43185
60 min and then	43198
60 min	43198
then	43209
1:500 streptavidin peroxidase -LRB- Jackson -RRB-	43217
1:500 streptavidin peroxidase	43217
Jackson	43248
60 min in the same buffer	43261
60 min	43261
the same buffer	43271
The immunoreactive product was visualized by incubating in 3,3 ′ - diaminobenzidine solution -LRB- DAB , 0.5 mg in 1 ml TTBS -RRB- with 0.01 % H2O2 for 1 -- 3 min .	43288
The immunoreactive product was visualized by incubating in 3,3 ′	43288
The immunoreactive product	43288
3,3 ′	43347
3,3	43347
diaminobenzidine solution -LRB- DAB , 0.5 mg in 1 ml TTBS -RRB- with 0.01 % H2O2 for 1	43352
diaminobenzidine solution -LRB- DAB , 0.5 mg in 1 ml TTBS -RRB-	43352
diaminobenzidine solution	43352
DAB , 0.5 mg in 1 ml TTBS	43379
DAB	43379
0.5 mg in 1 ml TTBS	43384
0.5 mg	43384
1 ml TTBS	43394
0.01 % H2O2 for 1	43409
0.01 % H2O2	43409
1	43424
3 min	43426
3	43426
min	43428
The sections	43433
hematoxylin	43525
Negative controls	43538
the lack of the primary antibody	43587
the lack	43587
the primary antibody	43599
The primary antibodies used for the paraffin sections	43621
The primary antibodies	43621
the paraffin sections	43653
monoclonal antibody against glial fibrillary acidic protein -LRB- GFAP , 1 : 1000 ; Neomarker , Fremont , CA -RRB- of astrocytes , and monoclonal antibody P0 -LRB- 1:1000 ; courtesy of Dr. Archelos , Austria -RRB- against the peripheral myelin protein	43679
monoclonal antibody against glial fibrillary acidic protein -LRB- GFAP , 1 : 1000 ; Neomarker , Fremont , CA -RRB- of astrocytes	43679
monoclonal antibody	43679
glial fibrillary acidic protein -LRB- GFAP , 1 : 1000 ; Neomarker , Fremont , CA -RRB- of astrocytes	43707
glial fibrillary acidic protein -LRB- GFAP , 1 : 1000 ; Neomarker , Fremont , CA -RRB-	43707
glial fibrillary acidic protein	43707
GFAP , 1	43740
GFAP	43740
1	43746
1000 ; Neomarker , Fremont , CA	43749
1000	43749
Neomarker , Fremont , CA	43755
astrocytes	43782
monoclonal antibody P0 -LRB- 1:1000 ; courtesy of Dr. Archelos , Austria -RRB- against the peripheral myelin protein	43798
monoclonal antibody P0 -LRB- 1:1000 ; courtesy of Dr. Archelos , Austria -RRB-	43798
monoclonal antibody P0	43798
1:1000 ; courtesy of Dr. Archelos , Austria	43822
1:1000	43822
courtesy of Dr. Archelos , Austria	43830
courtesy	43830
Dr. Archelos , Austria	43842
Dr. Archelos	43842
Austria	43856
the peripheral myelin protein	43873
4.8	43904
Quantitative analysis of tissue repair To quantitatively analyze the changes of repaired tissues and lesion cavities in size , the whole area , and the areas of spared tissues , repaired tissues and lesion cavities	43909
Quantitative analysis	43909
tissue repair	43934
the changes of repaired tissues and lesion cavities in size , the whole area , and the areas of spared tissues , repaired tissues and lesion cavities	43974
the changes	43974
tissues and lesion cavities	43998
size , the whole area , and the areas of spared tissues , repaired tissues and lesion cavities	44029
size	44029
the whole area	44035
the areas of spared tissues	44055
the areas	44055
spared tissues	44068
tissues and lesion cavities	44093
the cross sections	44149
the injury epicenter in each case	44173
the injury epicenter	44173
each case	44197
The paraffin sectionswere stainedwith hematoxylin and eosin and the Soft Imaging System GmbH -LRB- Version 1.20 , Olympus -RRB-	44208
The paraffin sectionswere stainedwith hematoxylin and eosin	44208
The paraffin sectionswere stainedwith hematoxylin	44208
eosin	44262
the Soft Imaging System GmbH -LRB- Version 1.20 , Olympus -RRB-	44272
the Soft Imaging System GmbH	44272
Version 1.20	44302
Olympus	44316
measurement	44338
The average percentage of spared tissues , repaired tissues and lesion cavities to the whole area of cross section in each group	44351
The average percentage	44351
spared tissues , repaired tissues and lesion cavities to the whole area of cross section in each group	44377
spared tissues	44377
tissues and lesion cavities	44402
the whole area of cross section in each group	44433
the whole area	44433
cross section in each group	44451
cross section	44451
each group	44468
mean ± SEM	44497
the comparisons between groups	44511
the comparisons	44511
groups	44535
The number for areameasurement in each group	44558
The number	44558
areameasurement in each group	44573
areameasurement	44573
each group	44592
the same as that for P0-positive myelin sheath counting	44606
that for P0-positive myelin sheath	44618
that	44618
P0-positive myelin sheath	44627
4.9	44663
P0-positive myelin sheath counting	44668
the present study	44706
the number of P0-positive myelin sheaths	44725
the number	44725
P0-positive myelin sheaths	44739
the light microscope -LRB- magnification : 30 × -RRB-	44784
the light microscope	44784
magnification : 30 ×	44806
magnification	44806
30 ×	44821
The area counted	44827
The area	44827
the repaired tissue , lesion cavity , and the spared tissue on the transverse sections -LRB- 2 -- 3 sections were counted in each case ; n ≥ 4 each group -RRB- at the injury epicenter	44853
the repaired tissue	44853
lesion cavity	44874
the spared tissue on the transverse sections -LRB- 2 -- 3 sections were counted in each case ; n ≥ 4 each group -RRB- at the injury epicenter	44893
the spared tissue on the transverse sections -LRB- 2 -- 3 sections were counted in each case ; n ≥ 4 each group -RRB-	44893
the spared tissue	44893
the transverse sections	44914
2 -- 3 sections were counted in each case ; n ≥ 4 each group	44939
2 -- 3	44939
sections	44943
each case ; n ≥ 4 each group	44968
each case	44968
n ≥ 4 each group	44979
n	44979
≥ 4 each group	44980
the injury epicenter	44998
rats	45023
scar ablation and transplantation	45038
almost no border	45073
tissues	45139
the merging of these two different tissues	45154
the merging	45154
these two different tissues	45169
all P0-positive myelin sheaths within the areas counted	45208
all P0-positive myelin sheaths	45208
the areas counted	45246
the areas	45246
a total number for each case	45281
a total number	45281
each case	45300
4.10	45311
Evaluation of hindlimb locomotor function The neurological outcome of hind limbs	45317
Evaluation	45317
hindlimb locomotor function The neurological outcome of hind limbs	45331
hindlimb locomotor function	45331
The neurological outcome of hind limbs	45359
The neurological outcome	45359
hind limbs	45387
the well-known open field scale , BBB rating scale -LRB- Basso et al. , 1995 ; 1996 -RRB-	45421
the well-known open field scale , BBB rating scale	45421
open field scale , BBB	45436
open field scale	45436
BBB	45454
Basso	45472
et al. , 1995 ; 1996	45478
et al.	45478
1995 ; 1996	45486
contusion injury	45505
the BBB scores	45523
1 day , 3 days , 7 days post-injury and once a week	45553
1 day	45553
3 days	45560
7 days post-injury	45568
once a week	45591
scar ablation and LP/OEC transplantation	45620
scar ablation	45620
LP/OEC transplantation	45638
the BBB scores	45662
the end of the experiment	45705
the end	45705
the experiment	45716
4.11	45732
Statistical analysis All quantitative data	45738
Statistical analysis	45738
All quantitative data	45759
mean ± SEM	45799
The analysis of all quantitative data	45809
The analysis	45809
all quantitative data	45825
one-way ANOVA for overall significance	45867
one-way ANOVA	45867
overall significance	45885
a post hoc LSD	45918
a post	45918
Student 's t test	45933
Student 's	45933
Results	45951
statistically significant at the level of p <	45975
the level of p	46004
the level	46004
p	46017
